BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zucman-rossi J, Villanueva A, Nault J, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239.e4. [DOI: 10.1053/j.gastro.2015.05.061] [Cited by in Crossref: 531] [Cited by in F6Publishing: 530] [Article Influence: 75.9] [Reference Citation Analysis]
Number Citing Articles
1 Xue M, Wu Y, Fan W, Guo J, Wei J, Wang H, Tan J, Wang Y, Yao W, Zhao Y, Li J. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma. Cancer Res Treat 2020;52:925-37. [PMID: 32229792 DOI: 10.4143/crt.2019.533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Nosaka T, Naito T, Hiramatsu K, Ohtani M, Nemoto T, Marusawa H, Ma N, Hiraku Y, Kawanishi S, Yamashita T, Kaneko S, Nakamoto Y. Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS One. 2017;12:e0185442. [PMID: 28968425 DOI: 10.1371/journal.pone.0185442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Svinarenko M, Katz SF, Tharehalli U, Mulaw MA, Maier HJ, Sunami Y, Fischer SK, Chen Y, Heurich S, Erkert L, Tannapfel A, Wirth T, Schirmbeck R, Seufferlein T, Lechel A. An IKK/NF-κB Activation/p53 Deletion Sequence Drives Liver Carcinogenesis and Tumor Differentiation. Cancers (Basel) 2019;11:E1410. [PMID: 31546614 DOI: 10.3390/cancers11101410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Wang X, Qiao J, Wang R. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20203263. [PMID: 33111935 DOI: 10.1042/BSR20203263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Allain C, Angenard G, Clément B, Coulouarn C. Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. Cancer Res 2016;76:6374-81. [PMID: 27634755 DOI: 10.1158/0008-5472.CAN-16-1559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
7 Mai H, Zhou B, Liu L, Yang F, Conran C, Ji Y, Hou J, Jiang D. Molecular pattern of lncRNAs in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:198. [PMID: 31097003 DOI: 10.1186/s13046-019-1213-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
8 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
9 Ziol M, Poté N, Amaddeo G, Laurent A, Nault J, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-rossi J, Barget N, Seror O, Ganne-carrié N, Paradis V, Calderaro J. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018;68:103-12. [DOI: 10.1002/hep.29762] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
10 Lian Y, Fan W, Huang Y, Wang H, Wang J, Zhou L, Wu X, Deng M, Huang Y. Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration. Oncol Res 2018;26:691-701. [PMID: 29117881 DOI: 10.3727/096504017X15101398724809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Barriocanal M, Prior C, Suarez B, Unfried JP, Razquin N, Hervás-Stubbs S, Sangro B, Segura V, Fortes P. Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth. J Immunol 2021;206:1932-42. [PMID: 33789981 DOI: 10.4049/jimmunol.1900776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ding Y, Sun Z, Zhang S, Li Y, Han X, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:7020637. [PMID: 34195281 DOI: 10.1155/2021/7020637] [Reference Citation Analysis]
13 Pinto Marques H, Gomes da Silva S, De Martin E, Agopian VG, Martins PN. Emerging biomarkers in HCC patients: Current status. Int J Surg 2020;82S:70-6. [PMID: 32344023 DOI: 10.1016/j.ijsu.2020.04.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Giovannini C, Fornari F, Piscaglia F, Gramantieri L. Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells 2021;10:521. [PMID: 33804511 DOI: 10.3390/cells10030521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
16 Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018;50:640-646. [PMID: 29636240 DOI: 10.1016/j.dld.2018.03.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
17 Nwosu ZC, Battello N, Rothley M, Piorońska W, Sitek B, Ebert MP, Hofmann U, Sleeman J, Wölfl S, Meyer C, Megger DA, Dooley S. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. J Exp Clin Cancer Res 2018;37:211. [PMID: 30176945 DOI: 10.1186/s13046-018-0872-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
18 Akasu M, Shimada S, Kabashima A, Akiyama Y, Shimokawa M, Akahoshi K, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Sci Rep 2021;11:16732. [PMID: 34429454 DOI: 10.1038/s41598-021-96167-0] [Reference Citation Analysis]
19 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
20 Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, Li ZN. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett. 2018;16:1593-1601. [PMID: 30008842 DOI: 10.3892/ol.2018.8825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen J, A Gingold J. Dysregulated PJA1-TGF-β signaling in cancer stem cell-associated liver cancers. Oncoscience 2020;7:88-95. [PMID: 33457451 DOI: 10.18632/oncoscience.522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liang Y, Feng Y, Zong M, Wei XF, Lee J, Feng Y, Li H, Yang GS, Wu ZJ, Fu XD, Feng GS. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET. Hepatology 2018;67:1807-22. [PMID: 29152756 DOI: 10.1002/hep.29661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
23 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
24 Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, Li Y, Wang J, Guo H, Huang QT, Zhong Q, Tan J, Qi L, Gong W, Hong Z, Li M, Zhao J, Peng T, Lu Y, Lim KHT, Boot A, Ono A, Chayama K, Zhang Z, Rozen SG, Teh BT, Wang XW, Nakagawa H, Zeng MS, Bai F, Zhang N. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell 2019;35:932-947.e8. [PMID: 31130341 DOI: 10.1016/j.ccell.2019.04.007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 20.3] [Reference Citation Analysis]
25 Kelly SL, Bird TG. The Evolution of the Use of Serum Alpha-fetoprotein in Clinical Liver Cancer Surveillance. J Immunobiol 2016;1:1000116. [PMID: 28133640 DOI: 10.4172/2476-1966.1000116] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
26 Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LLM, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Wang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY, Cheng AS, To KF. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun 2019;10:335. [PMID: 30659195 DOI: 10.1038/s41467-018-08245-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
27 Ferreira RG, Cardoso MV, de Souza Furtado KM, Espíndola KMM, Amorim RP, Monteiro MC. Epigenetic alterations caused by aflatoxin b1: a public health risk in the induction of hepatocellular carcinoma. Translational Research 2019;204:51-71. [DOI: 10.1016/j.trsl.2018.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
28 Yan Q, Tang Y, He F, Xue J, Zhou R, Zhang X, Luo H, Zhou D, Wang X. Global analysis of DNA methylation in hepatocellular carcinoma via a whole-genome bisulfite sequencing approach. Genomics 2021;113:3618-34. [PMID: 34461228 DOI: 10.1016/j.ygeno.2021.08.024] [Reference Citation Analysis]
29 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
30 Ben-Moshe S, Shapira Y, Moor AE, Manco R, Veg T, Bahar Halpern K, Itzkovitz S. Spatial sorting enables comprehensive characterization of liver zonation. Nat Metab 2019;1:899-911. [PMID: 31535084 DOI: 10.1038/s42255-019-0109-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
31 Amisaki M, Tsuchiya H, Sakabe T, Fujiwara Y, Shiota G. Identification of genes involved in the regulation of TERT in hepatocellular carcinoma. Cancer Sci 2019;110:550-60. [PMID: 30447097 DOI: 10.1111/cas.13884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
32 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Mabrouk NMK, Elkaffash DM, Abdel-Hadi M, Abdelmoneim SE, Saad ElDeen S, Gewaifel G, Elella KA, Osman M, Baddour N. Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4. Drug Target Insights 2020;14:1-11. [PMID: 33132693 DOI: 10.33393/dti.2020.1548] [Reference Citation Analysis]
34 Feder S, Bruckmann A, McMullen N, Sinal CJ, Buechler C. Chemerin Isoform-Specific Effects on Hepatocyte Migration and Immune Cell Inflammation. Int J Mol Sci 2020;21:E7205. [PMID: 33003572 DOI: 10.3390/ijms21197205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 76.7] [Reference Citation Analysis]
36 Nault JC, Datta S, Imbeaud S, Franconi A, Zucman-Rossi J. Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Mol Cell Oncol. 2016;3:e1095271. [PMID: 27308626 DOI: 10.1080/23723556.2015.1095271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
37 Nguyen T, Le A. The Metabolism of Renal Cell Carcinomas and Liver Cancer. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2018. pp. 107-18. [DOI: 10.1007/978-3-319-77736-8_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
39 Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association Française pour l’Etude du Foie (AFEF). Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45:101590. [PMID: 33780876 DOI: 10.1016/j.clinre.2020.101590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Reference Citation Analysis]
41 Gao J, Xi L, Yu R, Xu H, Wu M, Huang H. Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma. Front Oncol 2021;11:596789. [PMID: 33996539 DOI: 10.3389/fonc.2021.596789] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 2017;153:812-826. [PMID: 28624577 DOI: 10.1053/j.gastro.2017.06.007] [Cited by in Crossref: 265] [Cited by in F6Publishing: 272] [Article Influence: 53.0] [Reference Citation Analysis]
43 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
44 Zhu X, Hao M, Yu X, Lin W, Ma X, Xu Q, Cheng L, Kuang H. Dissecting the Pathogenesis of Diabetic Retinopathy Based on the Biological ceRNA Network and Genome Variation Disturbance. Comput Math Methods Med 2021;2021:9833142. [PMID: 34707685 DOI: 10.1155/2021/9833142] [Reference Citation Analysis]
45 Chappell G, Silva GO, Uehara T, Pogribny IP, Rusyn I. Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease. Cancer Med 2016;5:574-85. [PMID: 26778414 DOI: 10.1002/cam4.606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
46 Craig AJ, Villanueva A. Liver capsule: Molecular-based signatures in hepatocellular carcinoma. Hepatology 2016;63:2018. [PMID: 26856972 DOI: 10.1002/hep.28489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
48 Harris WP, Wong KM, Saha S, Dika IE, Abou-Alfa GK. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Semin Oncol 2018;45:116-23. [PMID: 30348531 DOI: 10.1053/j.seminoncol.2018.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
49 Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018;24:395-411. [PMID: 29530485 DOI: 10.1016/j.molmed.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
50 Zhao Y, Zhang L, Zhang Y, Meng B, Ying W, Qian X. Identification of hedgehog signaling as a potential oncogenic driver in an aggressive subclass of human hepatocellular carcinoma: A reanalysis of the TCGA cohort. Sci China Life Sci 2019;62:1481-91. [PMID: 31313086 DOI: 10.1007/s11427-019-9560-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 2016;22:199-211. [PMID: 27189732 DOI: 10.3350/cmh.2016.0101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
52 Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 2021;124:1388-97. [PMID: 33531690 DOI: 10.1038/s41416-021-01260-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Park SR, Ryu MH, Ryoo BY, Choi J. Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers (Basel) 2020;12:E1968. [PMID: 32698355 DOI: 10.3390/cancers12071968] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
54 Woo HG, Choi JH, Yoon S, Jee BA, Cho EJ, Lee JH, Yu SJ, Yoon JH, Yi NJ, Lee KW, Suh KS, Kim YJ. Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nat Commun 2017;8:839. [PMID: 29018224 DOI: 10.1038/s41467-017-00991-w] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
55 Danno K, Nakamura T, Okoso N, Nakamura N, Iguchi K, Iwadate Y, Kenmotsu T, Ikegawa M, Uemoto S, Yoshikawa K. Cracking pattern of tissue slices induced by external extension provides useful diagnostic information. Sci Rep 2018;8:12167. [PMID: 30111854 DOI: 10.1038/s41598-018-30662-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Timperi E, Barnaba V. Viral Hepatitides, Inflammation and Tumour Microenvironment. Adv Exp Med Biol 2020;1263:25-43. [PMID: 32588321 DOI: 10.1007/978-3-030-44518-8_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Andrisani O. Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma. Hepatoma Res 2021;7:12. [PMID: 33614973 DOI: 10.20517/2394-5079.2020.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zhu GQ, Liu WR, Tang Z, Qu WF, Fang Y, Jiang XF, Song SS, Wang H, Tao CY, Zhou PY, Huang R, Gao J, Sun HX, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Shi YH. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Mol Oncol 2021. [PMID: 34543520 DOI: 10.1002/1878-0261.13105] [Reference Citation Analysis]
59 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Reference Citation Analysis]
60 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
61 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
62 Liu J, Zeng S, Wang Y, Yu J, Ouyang Q, Hu L, Zhou D, Lin G, Sun Y. Essentiality of CTNNB1 in Malignant Transformation of Human Embryonic Stem Cells under Long-Term Suboptimal Conditions. Stem Cells Int 2020;2020:5823676. [PMID: 33029148 DOI: 10.1155/2020/5823676] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Zhou ZG, Chen JB, Zhang RX, Ye L, Wang JC, Pan YX, Wang XH, Li WX, Zhang YJ, Xu L, Chen MS. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Commun (Lond) 2020;40:355-69. [PMID: 32609436 DOI: 10.1002/cac2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Pez F, Gifu P, Degli-Esposti D, Fares N, Lopez A, Lefrançois L, Michelet M, Rivoire M, Bancel B, Sylla BS, Herceg Z, Merle P, Caron de Fromentel C. In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties. Exp Cell Res 2019;384:111643. [PMID: 31557464 DOI: 10.1016/j.yexcr.2019.111643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:219-231.e1. [PMID: 32781086 DOI: 10.1053/j.gastro.2020.08.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
66 Kong L, Liu P, Zheng M, Xue B, Liang K, Tan X. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. Epigenomics 2020;12:507-24. [PMID: 32048534 DOI: 10.2217/epi-2019-0374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
67 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
68 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
69 Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, Jochems F, Yang Y, Bosma A, Hijmans EM, de Groot MHP, Vegna S, Cui D, Zhou Y, Ling J, Wang H, Guo Y, Zheng X, Isima N, Wu H, Sun C, Beijersbergen RL, Akkari L, Zhou W, Zhai B, Qin W, Bernards R. EGFR activation limits the response of liver cancer to lenvatinib. Nature 2021;595:730-4. [PMID: 34290403 DOI: 10.1038/s41586-021-03741-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Denis JA, Guillerm E, Coulet F, Larsen AK, Lacorte JM. The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. Mol Diagn Ther 2017;21:587-600. [PMID: 28667577 DOI: 10.1007/s40291-017-0287-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
71 Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, Tournier E, Dumont F, Sanson R, Calderaro J, Zucman-Rossi J, Vasseur-Cognet M, Just PA, Terris B, Perret C, Gilgenkrantz H. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation. J Hepatol 2018;68:1203-13. [PMID: 29525529 DOI: 10.1016/j.jhep.2017.12.018] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
72 Dong H, Zhang Y, Xu Y, Ma R, Liu L, Luo C, Jiang W. Downregulation of long non-coding RNA MEG3 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1. Acta Biochimica et Biophysica Sinica 2019;51:645-52. [DOI: 10.1093/abbs/gmz046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457-470. [PMID: 30598371 DOI: 10.1016/j.ebiom.2018.12.058] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 15.5] [Reference Citation Analysis]
74 Zhang K, Zhang M, Luo Z, Wen Z, Yan X. The dichotomous role of TGF-β in controlling liver cancer cell survival and proliferation. J Genet Genomics 2020;47:497-512. [PMID: 33339765 DOI: 10.1016/j.jgg.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
76 Schneller D, Angel P; Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany, Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Cellular Origin of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 1-28. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
77 Md Tahir P, Liew WP, Lee SY, Ang AF, Lee SH, Mohamed R, Halis R. Diversity and characterization of lignocellulolytic fungi isolated from oil palm empty fruit bunch, and identification of influencing factors of natural composting process. Waste Manag 2019;100:128-37. [PMID: 31536923 DOI: 10.1016/j.wasman.2019.09.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Luo Y, Ye J, Wei J, Zhang J, Li Y. Long non‑coding RNA‑based risk scoring system predicts prognosis of alcohol‑related hepatocellular carcinoma. Mol Med Rep 2020;22:997-1007. [PMID: 32468063 DOI: 10.3892/mmr.2020.11179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Huang WT, Chen ZX, He RQ, Wu YZ, Yin SY, Liang XN, Chen G, Yang H, Peng ZG, Yang LH. Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis. Onco Targets Ther 2016;9:5061-71. [PMID: 27574447 DOI: 10.2147/OTT.S111431] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
80 Sladky VC, Eichin F, Reiberger T, Villunger A. Polyploidy control in hepatic health and disease. J Hepatol 2021:S0168-8278(21)01879-1. [PMID: 34228992 DOI: 10.1016/j.jhep.2021.06.030] [Reference Citation Analysis]
81 Rastogi A, Maiwall R, Ramakrishna G, Modi S, Taneja K, Bihari C, Kumar G, Patil N, Thapar S, Choudhury AK, Mukund A, Pamecha V, Sarin SK. Hepatocellular carcinoma: Clinicopathologic associations amidst marked phenotypic heterogeneity. Pathol Res Pract 2021;217:153290. [PMID: 33307344 DOI: 10.1016/j.prp.2020.153290] [Reference Citation Analysis]
82 Shi HS, Wang S, Li MJ, Wu LQ. A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report. Visc Med 2021;37:116-9. [PMID: 33981751 DOI: 10.1159/000505950] [Reference Citation Analysis]
83 Chen C, Lv Q, Li Y, Jin YH. The Anti-Tumor Effect and Underlying Apoptotic Mechanism of Ginsenoside Rk1 and Rg5 in Human Liver Cancer Cells. Molecules 2021;26:3926. [PMID: 34199025 DOI: 10.3390/molecules26133926] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Ding CH, Deng LF, Chen F, Ding K, Chen WS, Xie WF, Zhang X. p.Q511L mutation of HNF1α in hepatocellular carcinoma suppresses the transcriptional activity and the anti-tumor effect of HNF1α. Biochem Biophys Res Commun 2018;495:86-91. [PMID: 29101032 DOI: 10.1016/j.bbrc.2017.10.174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
85 Martins-Filho SN, Alves VAF, Wakamatsu A, Maeda M, Craig AJ, Assato AK, Villacorta-Martin C, D'Avola D, Labgaa I, Carrilho FJ, Thung SN, Villanueva A. A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology. 2019;74:718-730. [PMID: 30636011 DOI: 10.1111/his.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
86 Huang R, Chen Z, Li W, Fan C, Liu J. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma. Int J Oncol 2020;56:1199-211. [PMID: 32319580 DOI: 10.3892/ijo.2020.4998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
88 Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019;116:56-66. [PMID: 31173963 DOI: 10.1016/j.ejca.2019.04.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
89 Allaire M, Nault J. Molecular targets for HCC and future treatments. Journal of Hepatology 2017;66:234-5. [DOI: 10.1016/j.jhep.2016.07.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
90 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
91 Charawi S, Just PA, Savall M, Abitbol S, Traore M, Metzger N, Ravinger R, Cavard C, Terris B, Perret C. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC. J Pathol 2019;247:435-43. [PMID: 30566242 DOI: 10.1002/path.5202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
92 Bévant K, Desoteux M, Angenard G, Pineau R, Caruso S, Louis C, Papoutsoglou P, Sulpice L, Gilot D, Zucman-Rossi J, Coulouarn C. TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatol Commun 2021. [PMID: 34825776 DOI: 10.1002/hep4.1866] [Reference Citation Analysis]
93 Nomura Y, Yamashita T, Oishi N, Nio K, Hayashi T, Yoshida M, Hayashi T, Hashiba T, Asahina Y, Okada H, Sunagozaka H, Takatori H, Honda M, Kaneko S. De Novo Emergence of Mesenchymal Stem-Like CD105+ Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma. Transl Oncol 2017;10:184-9. [PMID: 28182993 DOI: 10.1016/j.tranon.2017.01.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
94 Chen M, Zhang B, Topatana W, Cao J, Zhu H, Juengpanich S, Mao Q, Yu H, Cai X. Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning. NPJ Precis Oncol. 2020;4:14. [PMID: 32550270 DOI: 10.1038/s41698-020-0120-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
95 Iwako H, Tashiro H, Okimoto S, Yamaguchi M, Abe T, Kuroda S, Kobayashi T, Ohdan H. Antithrombin Insufficiency Promotes Susceptibility to Liver Tumorigenesis. J Surg Res 2019;236:198-208. [PMID: 30694755 DOI: 10.1016/j.jss.2018.11.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Xue R, Li J, Bai F, Wang X, Ji J, Lu Y. A race to uncover a panoramic view of primary liver cancer. Cancer Biol Med 2017;14:335-40. [PMID: 29372099 DOI: 10.20892/j.issn.2095-3941.2017.0112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
97 Li X, Wang H, Li T, Wang L, Wu X, Liu J, Xu Y, Wei W. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer 2020;44:100516. [PMID: 31836136 DOI: 10.1016/j.currproblcancer.2019.100516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
98 Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp Mol Med 2018;50:e417. [PMID: 29303510 DOI: 10.1038/emm.2017.158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
99 Dong F, Yang Q, Wu Z, Hu X, Shi D, Feng M, Li J, Zhu L, Jiang S, Bao Z. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses. Biomed Pharmacother 2019;114:108856. [PMID: 30981109 DOI: 10.1016/j.biopha.2019.108856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
100 Lee J, Liao R, Wang G, Yang BH, Luo X, Varki NM, Qiu SJ, Ren B, Fu W, Feng GS. Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. Cell Rep 2017;21:1870-82. [PMID: 29141219 DOI: 10.1016/j.celrep.2017.10.064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
101 Kagey MH, He X. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol. 2017;174:4637-4650. [PMID: 28574171 DOI: 10.1111/bph.13894] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
102 Yamashita T, Nault JC. Stemness of liver cancer: From hepatitis B virus to Wnt activation. J Hepatol 2016;65:873-5. [PMID: 27449917 DOI: 10.1016/j.jhep.2016.07.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
103 Woo HG, Kim YJ. Multiplatform Genomic Roadmap of Hepatocellular Carcinoma: A Matter of Molecular Heterogeneity. Hepatology 2018;68:2029-32. [PMID: 29637589 DOI: 10.1002/hep.29925] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
104 Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatol Res 2021;51:5-18. [DOI: 10.1111/hepr.13539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
105 Yang C, Huang X, Liu Z, Qin W, Wang C. Metabolism-associated molecular classification of hepatocellular carcinoma.Mol Oncol. 2020;14:896-913. [PMID: 31955511 DOI: 10.1002/1878-0261.12639] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
106 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
107 Caviglia GP, Olivero A, Rosso C, Bosco C, Ribaldone DG, Fagoonee S. Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. Minerva Biotecnol 2018;30. [DOI: 10.23736/s1120-4826.18.02428-x] [Cited by in Crossref: 12] [Article Influence: 3.0] [Reference Citation Analysis]
108 Hu J, Zhang ZQ, Zhu W, Wu ZR, You Y, Liu Y, Su DW, Wang YB, Gong JP. Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background. Carcinogenesis 2020;41:1576-82. [PMID: 32188964 DOI: 10.1093/carcin/bgaa024] [Reference Citation Analysis]
109 Stickel F, Hampe J. Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk. Lancet Oncol 2022;23:14-6. [PMID: 34902337 DOI: 10.1016/S1470-2045(21)00663-X] [Reference Citation Analysis]
110 Tang Y, Yang X, Feng K, Hu C, Li S. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:174-83. [PMID: 33708434 DOI: 10.21037/jgo-20-534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
111 Cui G, Martin RC, Jin H, Liu X, Pandit H, Zhao H, Cai L, Zhang P, Li W, Li Y. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. J Exp Clin Cancer Res. 2018;37:136. [PMID: 29973237 DOI: 10.1186/s13046-018-0781-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
112 Tharehalli U, Svinarenko M, Lechel A. Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. Stem Cells Int 2019;2019:3831213. [PMID: 30915124 DOI: 10.1155/2019/3831213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Lee HH, Kim D, Jung J, Kang H, Cho H. NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B. Int J Mol Sci 2021;22:9285. [PMID: 34502191 DOI: 10.3390/ijms22179285] [Reference Citation Analysis]
114 Chang TT, Thakar D, Weaver VM. Force-dependent breaching of the basement membrane. Matrix Biol 2017;57-58:178-89. [PMID: 28025167 DOI: 10.1016/j.matbio.2016.12.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
115 Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38:2-11. [PMID: 27838634 DOI: 10.1093/carcin/bgw118] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
116 de Castro RO, Previato L, Goitea V, Felberg A, Guiraldelli MF, Filiberti A, Pezza RJ. The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes. J Biol Chem 2017;292:8459-71. [PMID: 28381560 DOI: 10.1074/jbc.M117.778183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
117 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
118 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
119 Wang X, Zhou J, Xu M, Yan Y, Huang L, Kuang Y, Liu Y, Li P, Zheng W, Liu H, Jia B. A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer. Cancer Manag Res 2018;10:5799-806. [PMID: 30510449 DOI: 10.2147/CMAR.S178732] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
120 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
121 Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis. Hepatology 2021;73:644-60. [PMID: 32298475 DOI: 10.1002/hep.31280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
122 Gong G, Tang X, Zhang J, Liang X, Yang J, Li Q. Phenylboronic Acid-Modified Polyamidoamine Mediated the Transfection of Polo-Like Kinase-1 siRNA to Achieve an Anti-Tumor Efficacy. Int J Nanomedicine 2021;16:8037-48. [PMID: 34934312 DOI: 10.2147/IJN.S329433] [Reference Citation Analysis]
123 Wang G, Luo X, Liang Y, Kaneko K, Li H, Fu XD, Feng GS. A tumorigenic index for quantitative analysis of liver cancer initiation and progression. Proc Natl Acad Sci U S A 2019:201911193. [PMID: 31843886 DOI: 10.1073/pnas.1911193116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-152. [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
125 Qin P, Zhang M, Liu X, Dong Z. Immunogenomic Landscape Analysis of Prognostic Immune-Related Genes in Hepatocellular Carcinoma. J Healthc Eng 2021;2021:3761858. [PMID: 34745496 DOI: 10.1155/2021/3761858] [Reference Citation Analysis]
126 Ishii T, Tamura A, Shibata T, Kuroda K, Kanda T, Sugiyama M, Mizokami M, Moriyama M. Analysis of HBV Genomes Integrated into the Genomes of Human Hepatoma PLC/PRF/5 Cells by HBV Sequence Capture-Based Next-Generation Sequencing. Genes (Basel) 2020;11:E661. [PMID: 32570699 DOI: 10.3390/genes11060661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
127 Xin B, Yamamoto M, Fujii K, Ooshio T, Chen X, Okada Y, Watanabe K, Miyokawa N, Furukawa H, Nishikawa Y. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. Oncogene 2017;36:5087-97. [PMID: 28481866 DOI: 10.1038/onc.2017.114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
128 Kwee SA, Tiirikainen M. Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Res 2021;7:8. [PMID: 33553649 DOI: 10.20517/2394-5079.2020.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Luo X, Liao R, Hanley KL, Zhu HH, Malo KN, Hernandez C, Wei X, Varki NM, Alderson N, Chu C, Li S, Fan J, Loomba R, Qiu SJ, Feng GS. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. Cell Rep 2016;17:2979-93. [PMID: 27974211 DOI: 10.1016/j.celrep.2016.11.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
130 Wang W, Liu P, Lavrijsen M, Li S, Zhang R, Li S, van de Geer WS, van de Werken HJG, Peppelenbosch MP, Smits R. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines. Sci Rep 2021;11:7470. [PMID: 33811251 DOI: 10.1038/s41598-021-87091-4] [Reference Citation Analysis]
131 Liu X, Liu F, Gao S, Reske J, Li A, Wu CL, Yang C, Chen F, Luo R, Xiao H. A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Lett 2017;391:152-61. [PMID: 28137631 DOI: 10.1016/j.canlet.2017.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
132 Ge Z, Helmijr JCA, Jansen MPHM, Boor PPC, Noordam L, Peppelenbosch M, Kwekkeboom J, Kraan J, Sprengers D. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Transl Oncol 2021;14:101073. [PMID: 33915518 DOI: 10.1016/j.tranon.2021.101073] [Reference Citation Analysis]
133 Li X, Wu Y, Suo P, Liu G, Li L, Zhang X, Chen S, Xu M, Song L. Identification of a novel germline frameshift mutation p.D300fs of PMS1 in a patient with hepatocellular carcinoma: A case report and literature review. Medicine (Baltimore) 2020;99:e19076. [PMID: 32000458 DOI: 10.1097/MD.0000000000019076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Yuan X, Cheng G, Yu J, Zheng S, Sun C, Sun Q, Li K, Lin Z, Liu T, Li P, Xu Y, Kong F, Bjorkholm M, Xu D. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget 2017;8:23120-9. [PMID: 28416747 DOI: 10.18632/oncotarget.15498] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
135 Oversoe SK, Clement MS, Weber B, Grønbæk H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer 2021;21:376. [PMID: 33827453 DOI: 10.1186/s12885-021-08103-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Lu Y, Duan Y, Xu Q, Zhang L, Chen W, Qu Z, Wu B, Liu W, Shi L, Wu D, Yang Y, Sun D, Chen X. Circulating exosome-derived bona fide long non-coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma. J Cell Mol Med. 2020;24:1311-1318. [PMID: 31811749 DOI: 10.1111/jcmm.14783] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
137 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
138 Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L, Gu J. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics. 2018;16:269-275. [PMID: 30266410 DOI: 10.1016/j.gpb.2018.07.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
139 Yopp AC, Parikh ND, Singal AG. Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System? Clinical Gastroenterology and Hepatology 2017;15:756-8. [DOI: 10.1016/j.cgh.2016.12.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38. [PMID: 28532995 DOI: 10.1016/j.jhep.2017.05.014] [Cited by in Crossref: 222] [Cited by in F6Publishing: 213] [Article Influence: 44.4] [Reference Citation Analysis]
141 Huang XY, Huang ZL, Zhang PB, Huang XY, Huang J, Wang HC, Xu B, Zhou J, Tang ZY. CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma. Front Oncol 2019;9:392. [PMID: 31157168 DOI: 10.3389/fonc.2019.00392] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
142 Jang JW, Kim JS, Kim HS, Tak KY, Lee SK, Nam HC, Sung PS, Kim CM, Park JY, Bae SH, Choi JY, Yoon SK. Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2160. [PMID: 33946181 DOI: 10.3390/cancers13092160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Li W, Jiang X, Jin X, Yan W, Liu Y, Li D, Zhao Z. Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction. Medicine (Baltimore) 2020;99:e19322. [PMID: 32282694 DOI: 10.1097/MD.0000000000019322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
144 Kong F, Kong D, Yang X, Yuan D, Zhang N, Hua X, You H, Zheng K, Tang R. Integrative analysis of highly mutated genes in hepatitis B virus-related hepatic carcinoma. Cancer Med 2020;9:2462-79. [PMID: 32017470 DOI: 10.1002/cam4.2903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Xu P, Luo A, Xiong C, Ren H, Yan L, Luo Q. SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway. Cancer Cell Int 2022;22:1. [PMID: 34980127 DOI: 10.1186/s12935-021-02402-z] [Reference Citation Analysis]
146 Lee K, Kim S, Lee Y, Lee H, Lee Y, Park H, Nahm JH, Ahn S, Yu SJ, Lee K, Kim H. The Clinicopathological and Prognostic Significance of Nrf2 and Keap1 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2128. [PMID: 32751896 DOI: 10.3390/cancers12082128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
147 Sarcognato S, García-Lezana T, Villanueva A. Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:62-5. [PMID: 31508222 DOI: 10.1002/cld.810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
148 Liu T, Xie XL, Zhou X, Chen SX, Wang YJ, Shi LP, Chen SJ, Wang YJ, Wang SL, Zhang JN, Dou SY, Jiang XY, Cui RL, Jiang HQ. Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4667-4686 [PMID: 34366628 DOI: 10.3748/wjg.v27.i28.4667] [Reference Citation Analysis]
149 Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020;5:241. [PMID: 33077733 DOI: 10.1038/s41392-020-00358-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
150 Bedossa P, Paradis V, Zucman-rossi J. Cellular and Molecular Techniques. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 88-110. [DOI: 10.1016/b978-0-7020-6697-9.00002-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Peng T, Wonganan O, Zhang Z, Yu J, Xi R, Cao Y, Suksamrarn A, Zhang G, Wang F. A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase. Int J Mol Sci 2021;22:3354. [PMID: 33805945 DOI: 10.3390/ijms22073354] [Reference Citation Analysis]
152 Lefort C, Cani PD. The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism. Cells 2021;10:400. [PMID: 33669184 DOI: 10.3390/cells10020400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118:248-257. [PMID: 29123264 DOI: 10.1038/bjc.2017.386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
154 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Ma YH, Dou WT, Pan YF, Dong LW, Tan YX, He XP, Tian H, Wang HY. Fluorogenic 2D Peptidosheet Unravels CD47 as a Potential Biomarker for Profiling Hepatocellular Carcinoma and Cholangiocarcinoma Tissues. Adv Mater 2017;29. [PMID: 27869342 DOI: 10.1002/adma.201604253] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
156 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
157 Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI, Borozan I, Brenner H, Brezina S, Buchanan DD, Cao Y, Chan AT, Chang-Claude J, Connolly CM, Drew DA, Farris AB 3rd, Figueiredo JC, French AJ, Fuchs CS, Garraway LA, Gruber S, Guinter MA, Hamilton SR, Harlid S, Heisler LE, Hidaka A, Hopper JL, Huang WY, Huyghe JR, Jenkins MA, Krzyzanowski PM, Lemire M, Lin Y, Luo X, Mardis ER, McPherson JD, Miller JK, Moreno V, Mu XJ, Nishihara R, Papadopoulos N, Pasternack D, Quist MJ, Rafikova A, Reid EEG, Shinbrot E, Shirts BH, Stein LD, Teney CD, Timms L, Um CY, Van Guelpen B, Van Tassel M, Wang X, Wheeler DA, Yung CK, Hsu L, Ogino S, Gsur A, Newcomb PA, Gallinger S, Hoffmeister M, Campbell PT, Thibodeau SN, Sun W, Hudson TJ, Peters U. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun 2020;11:3644. [PMID: 32686686 DOI: 10.1038/s41467-020-17386-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
158 Ding D, Huang H, Li Q, Yu W, Wang C, Ma H, Wu J, Dang Y, Yu L, Jiang W. NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2. Cell Death Discov 2020;6:3. [PMID: 32123579 DOI: 10.1038/s41420-020-0236-9] [Reference Citation Analysis]
159 Liu P, Liang B, Liu M, Lebbink JHG, Li S, Qian M, Lavrijsen M, Peppelenbosch MP, Chen X, Smits R. Oncogenic Mutations in Armadillo Repeats 5 and 6 of β-Catenin Reduce Binding to APC, Increasing Signaling and Transcription of Target Genes. Gastroenterology 2020;158:1029-1043.e10. [PMID: 31857074 DOI: 10.1053/j.gastro.2019.11.302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
160 Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
161 Yu JI, Choi C, Shin SW, Son A, Lee GH, Kim SY, Park HC. Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation. Sci Rep 2017;7:14986. [PMID: 29118323 DOI: 10.1038/s41598-017-15165-3] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
162 Yu L, Kim J, Jiang L, Feng B, Ying Y, Ji KY, Tang Q, Chen W, Mai T, Dou W, Zhou J, Xiang LY, He YF, Yang D, Li Q, Fu X, Xu Y. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat Commun 2020;11:708. [PMID: 32024842 DOI: 10.1038/s41467-020-14437-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
163 Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang X, Huang H, Ling Q, Zheng S. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med 2021. [PMID: 34331411 DOI: 10.1002/cam4.4162] [Reference Citation Analysis]
164 Ueno A, Masugi Y, Yamazaki K, Kurebayashi Y, Tsujikawa H, Effendi K, Ojima H, Sakamoto M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 2020;70:140-54. [PMID: 31908112 DOI: 10.1111/pin.12895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
165 Wang L, Zhang Z, Li Y, Wan Y, Xing B. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2480-505. [PMID: 33411682 DOI: 10.18632/aging.202281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
166 Liu P, Liang SQ, Zheng C, Mintzer E, Zhao YG, Ponnienselvan K, Mir A, Sontheimer EJ, Gao G, Flotte TR, Wolfe SA, Xue W. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun 2021;12:2121. [PMID: 33837189 DOI: 10.1038/s41467-021-22295-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
167 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1322-1331 [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
168 Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7:2641-2653. [PMID: 29733511 DOI: 10.1002/cam4.1517] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
169 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 28.3] [Reference Citation Analysis]
170 Caraballo Galva LD, Cai L, Shao Y, He Y. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. J Genet Genomics. 2020;47:1-15. [PMID: 32089500 DOI: 10.1016/j.jgg.2020.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
171 Wrighton PJ, Oderberg IM, Goessling W. There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2019;8:347-63. [PMID: 31108233 DOI: 10.1016/j.jcmgh.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
172 Wei J, Fang DL, Zhou W, He YF. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes. J Gastrointest Oncol 2021;12:1860-72. [PMID: 34532134 DOI: 10.21037/jgo-21-378] [Reference Citation Analysis]
173 Ren Y, Yang L, Li M, Wang J, Yan H, Ma N, Liu W, Wang L, Gao X, Gao P, Li T, Liu D. 4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients. Sci Rep 2021;11:16982. [PMID: 34417517 DOI: 10.1038/s41598-021-96581-4] [Reference Citation Analysis]
174 Nakatsuka T, Tateishi K, Kudo Y, Yamamoto K, Nakagawa H, Fujiwara H, Takahashi R, Miyabayashi K, Asaoka Y, Tanaka Y, Ijichi H, Hirata Y, Otsuka M, Kato M, Sakai J, Tachibana M, Aburatani H, Shinkai Y, Koike K. Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene 2017;36:6262-71. [DOI: 10.1038/onc.2017.222] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
175 Zhu Y, Wang Q, Lin H, Chen K, Zheng C, Chen L, Ma S, Liao W, Bin J, Liao Y. Characterizing a long-term chronic heart failure model by transcriptomic alterations and monitoring of cardiac remodeling. Aging (Albany NY) 2021;13:13585-614. [PMID: 33891565 DOI: 10.18632/aging.202879] [Reference Citation Analysis]
176 Tyraskis A, Deganello A, Sellars M, De Vito C, Thompson R, Quaglia A, Heaton N, Davenport M. Portal venous deprivation in patients with portosystemic shunts and its effect on liver tumors. J Pediatr Surg 2020;55:651-4. [PMID: 31279480 DOI: 10.1016/j.jpedsurg.2019.05.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Song YZ, Li X, Li W, Wang Z, Li K, Xie FL, Zhang F. Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas. World J Gastroenterol 2018; 24(28): 3145-3154 [PMID: 30065560 DOI: 10.3748/wjg.v24.i28.3145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
179 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 13.0] [Reference Citation Analysis]
180 Li F, Wang J, Wu N, Zhang H, Li Z, Wei N. H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. Biochem Biophys Res Commun 2019;520:93-8. [PMID: 31582208 DOI: 10.1016/j.bbrc.2019.09.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
181 Jefremow A, Neurath MF, Waldner MJ. CRISPR/Cas9 in Gastrointestinal Malignancies. Front Cell Dev Biol 2021;9:727217. [PMID: 34912798 DOI: 10.3389/fcell.2021.727217] [Reference Citation Analysis]
182 Fezza M, Moussa M, Aoun R, Haber R, Hilal G. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1. PLoS One 2019;14:e0223252. [PMID: 31568519 DOI: 10.1371/journal.pone.0223252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
183 Nault J, Ningarhari M, Rebouissou S, Zucman-rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544-58. [DOI: 10.1038/s41575-019-0165-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 18.3] [Reference Citation Analysis]
184 Hou JY, Wu HY, He RQ, Lin P, Dang YW, Chen G. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases. Pathol Res Pract 2019;215:177-94. [PMID: 30473171 DOI: 10.1016/j.prp.2018.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
185 Wang C, Wang H, Lieftink C, du Chatinier A, Gao D, Jin G, Jin H, Beijersbergen RL, Qin W, Bernards R. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 2020;69:727-36. [PMID: 31519701 DOI: 10.1136/gutjnl-2019-318506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
186 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
187 Xing JL, Wang YX, Du SD. Application and research progress of in vitro liver cancer cell culture models. Shijie Huaren Xiaohua Zazhi 2021; 29(11): 563-570 [DOI: 10.11569/wcjd.v29.i11.563] [Reference Citation Analysis]
188 Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J Hepatol. 2016;65:296-304. [PMID: 27130844 DOI: 10.1016/j.jhep.2016.04.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
189 Howell J, Thompson AJ. Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind. Gastroenterology 2017;152:1282-4. [PMID: 28363642 DOI: 10.1053/j.gastro.2017.03.025] [Reference Citation Analysis]
190 Martins-Filho SN, Paiva C, Azevedo RS, Alves VAF. Histological Grading of Hepatocellular Carcinoma-A Systematic Review of Literature. Front Med (Lausanne). 2017;4:193. [PMID: 29209611 DOI: 10.3389/fmed.2017.00193] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
191 Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, de Knegt RJ, Boonstra A. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. Gastroenterology 2018; 154: 515-517. e3. [PMID: 29102620 DOI: 10.1053/j.gastro.2017.10.035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
192 Xue W, Wang XW. The search for precision models clinically relevant to human liver cancer. Hepat Oncol 2015;2:315-9. [PMID: 30191010 DOI: 10.2217/hep.15.24] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
193 Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, Ponziani FR, Rendina M, Russo FP, Sacco R, Viganò M, Vitale A, Trevisani F; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers (Basel) 2019;11:E1689. [PMID: 31671581 DOI: 10.3390/cancers11111689] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
194 Sulas P, Di Tommaso L, Novello C, Rizzo F, Rinaldi A, Weisz A, Columbano A, Roncalli M. A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development. Am J Pathol. 2018;188:785-794. [PMID: 29248455 DOI: 10.1016/j.ajpath.2017.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
195 Zhong Y, Li Y, Song T, Zhang D. MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. Physiol Genomics 2019;51:500-5. [PMID: 31251699 DOI: 10.1152/physiolgenomics.00019.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
196 Zhou S, Zhou Z, Hu Z, Song C, Luo Y, Luo C, Xin H, Yang X, Shi Y, Wang Z, Huang X, Cao Y, Fan J, Zhou J. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. Journal of Hepatology 2019;71:1152-63. [DOI: 10.1016/j.jhep.2019.07.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
197 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer. 2017;12:27. [PMID: 28529542 DOI: 10.1186/s13027-017-0138-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
198 Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 2021;74:893-906. [PMID: 33197513 DOI: 10.1016/j.jhep.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 van der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, Tohme S, Loughran P, O'Doherty RM, Minervini MI, Huang H, Simmons RL, Tsung A. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2018;68:1347-1360. [PMID: 29631332 DOI: 10.1002/hep.29914] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 26.3] [Reference Citation Analysis]
201 In der Stroth L, Tharehalli U, Günes C, Lechel A. Telomeres and Telomerase in the Development of Liver Cancer. Cancers (Basel) 2020;12:E2048. [PMID: 32722302 DOI: 10.3390/cancers12082048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
202 Chae WJ, Bothwell ALM. Dickkopf1: An immunomodulatory ligand and Wnt antagonist in pathological inflammation. Differentiation 2019;108:33-9. [PMID: 31221431 DOI: 10.1016/j.diff.2019.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
203 Zhou M, Chen X, Bai H, Sun Y, Zhang Z, Li S, Wang X, Zeng M. RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma. DNA Cell Biol 2021;40:1418-27. [PMID: 34767735 DOI: 10.1089/dna.2021.0473] [Reference Citation Analysis]
204 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
205 Yim SY, Lee J. The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma. J Liver Cancer 2019;19:97-107. [DOI: 10.17998/jlc.19.2.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
206 Liu X, Huang Y, Jiang C, Ou H, Guo B, Liao H, Li X, Yang D. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis 2016;48:953-60. [PMID: 27257051 DOI: 10.1016/j.dld.2016.04.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
207 Solinas A, Calvisi DF. Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer? Hepatology 2016;64:1847-9. [PMID: 27618225 DOI: 10.1002/hep.28803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
208 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2021;73 Suppl 1:115-127. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
209 Lin T, Gu J, Qu K, Zhang X, Ma X, Miao R, Xiang X, Fu Y, Niu W, She J, Liu C. A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients' prognosis. Aging (Albany NY) 2018;10:2480-97. [PMID: 30243023 DOI: 10.18632/aging.101563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
210 Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer 2020;20:937. [PMID: 32993594 DOI: 10.1186/s12885-020-07105-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 de Conti A, Tryndyak V, Heidor R, Jimenez L, Moreno FS, Beland FA, Rusyn I, Pogribny IP. Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis. J Nutr Biochem 2020;86:108496. [PMID: 32920087 DOI: 10.1016/j.jnutbio.2020.108496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Paradis V. Hepatocellular Carcinomas: Towards a pathomolecular approach. Liver Int 2021;41 Suppl 1:83-8. [PMID: 34155797 DOI: 10.1111/liv.14867] [Reference Citation Analysis]
213 Kui X, Wang Y, Zhang C, Li H, Li Q, Ke Y, Wang L. Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study. BMC Med Genomics 2021;14:115. [PMID: 33906640 DOI: 10.1186/s12920-021-00963-6] [Reference Citation Analysis]
214 Taranto D, Ramirez CFA, Vegna S, de Groot MHP, de Wit N, Van Baalen M, Klarenbeek S, Akkari L. Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment. Curr Protoc 2021;1:e147. [PMID: 34101385 DOI: 10.1002/cpz1.147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Cassol F, Portal L, Richelme S, Dupont M, Boursier Y, Arechederra M, Auphan-Anezin N, Chasson L, Laprie C, Fernandez S, Balasse L, Lamballe F, Dono R, Guillet B, Lawrence T, Morel C, Maina F. Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography. iScience 2019;21:68-83. [PMID: 31655257 DOI: 10.1016/j.isci.2019.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
217 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
218 Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault J, Couchy G, Laurent A, Balabaud C, Bioulac‐sage P, Zucman‐rossi J. Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression. Hepatology 2016;64:2047-61. [DOI: 10.1002/hep.28638] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 21.2] [Reference Citation Analysis]
219 Zhao H, Yan L, Guo L, Sun H, Huang Q, Shao D, Jiang C, Shi J. Effects of Bacillus subtilis iturin A on HepG2 cells in vitro and vivo. AMB Express 2021;11:67. [PMID: 33970365 DOI: 10.1186/s13568-021-01226-4] [Reference Citation Analysis]
220 Fabrizio FP, Sparaneo A, Trombetta D, Muscarella LA. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. Oxid Med Cell Longev 2018;2018:2492063. [PMID: 29643973 DOI: 10.1155/2018/2492063] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
221 Rashed WM, Kandeil MA, Mahmoud MO, Maher D, Ezzat S, Abdel-Rahman MH. MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines. J Cancer Res Clin Oncol 2021;147:167-75. [PMID: 32980960 DOI: 10.1007/s00432-020-03395-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Zhang Z, Yang L, Yao X, Yang M, Li G. LncRNA-ZNF281 Interacts with miR-539 to Promote Hepatocellular Carcinoma Cell Invasion and Migration. Cancer Biother Radiopharm 2020;35:137-42. [PMID: 32073896 DOI: 10.1089/cbr.2019.3008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 330] [Cited by in F6Publishing: 335] [Article Influence: 66.0] [Reference Citation Analysis]
224 Nault JC. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator. Gastroenterology 2017;152:941-3. [PMID: 28259794 DOI: 10.1053/j.gastro.2017.02.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
226 Thorgeirsson SS. Stemness and reprogramming in liver cancer. Hepatology. 2016;63:1068-1070. [PMID: 26600290 DOI: 10.1002/hep.28362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
227 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
228 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
229 Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, Xu C, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. J Exp Clin Cancer Res 2021;40:262. [PMID: 34416907 DOI: 10.1186/s13046-021-02061-y] [Reference Citation Analysis]
230 Kim E, Kim D, Lee JS, Yoe J, Park J, Kim CJ, Jeong D, Kim S, Lee Y. Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology 2018;67:2287-301. [PMID: 29251790 DOI: 10.1002/hep.29738] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
231 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
232 Liu X, Liu Y, Liu Z, Zhang Y, Ma Y, Bai J, Yao H, Wang Y, Zhao X, Li R, Song X, Chen Y, Feng Z, Wang L. Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis. Biochem Biophys Rep 2021;28:101157. [PMID: 34754951 DOI: 10.1016/j.bbrep.2021.101157] [Reference Citation Analysis]
233 Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68:1025-1041. [PMID: 29603348 DOI: 10.1002/hep.29904] [Cited by in Crossref: 103] [Cited by in F6Publishing: 116] [Article Influence: 25.8] [Reference Citation Analysis]
234 Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 2020;72:990-1002. [PMID: 32044402 DOI: 10.1016/j.jhep.2020.01.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
235 Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology 2019;156:890-903. [PMID: 30578781 DOI: 10.1053/j.gastro.2018.11.071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
236 Du J, Zhu Z, Xu L, Chen X, Li X, Lan T, Li W, Yuan K, Zeng Y. ARHGEF11 promotes proliferation and epithelial-mesenchymal transition of hepatocellular carcinoma through activation of β-catenin pathway. Aging (Albany NY) 2020;12:20235-53. [PMID: 33122451 DOI: 10.18632/aging.103772] [Reference Citation Analysis]
237 Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, Wang L, Ma B, Li S, Wang W, Bolkestein M, Doukas M, Chen K, Ma Z, Bruno M, Sprengers D, Kwekkeboom J, van der Laan LJW, Smits R, Peppelenbosch MP, Pan Q. LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nat Commun 2020;11:1961. [PMID: 32327656 DOI: 10.1038/s41467-020-15846-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
238 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
239 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
240 Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology 2017;66:167-81. [PMID: 28370287 DOI: 10.1002/hep.29183] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 12.2] [Reference Citation Analysis]
241 Kurosaki S, Nakagawa H, Hayata Y, Kawamura S, Matsushita Y, Yamada T, Uchino K, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kinoshita H, Tanaka Y, Nakatsuka T, Hirata Y, Tateishi K, Koike K. Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis. JHEP Rep 2021;3:100315. [PMID: 34345813 DOI: 10.1016/j.jhepr.2021.100315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Chen K, Ding A, Ding Y, Ghanekar A. High-throughput flow cytometry screening of human hepatocellular carcinoma reveals CD146 to be a novel marker of tumor-initiating cells. Biochem Biophys Rep 2016;8:107-13. [PMID: 28955945 DOI: 10.1016/j.bbrep.2016.08.012] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
244 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
245 Calderaro J, Ziol M, Paradis V, Zucman-rossi J. Molecular and histological correlations in liver cancer. Journal of Hepatology 2019;71:616-30. [DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 24.7] [Reference Citation Analysis]
246 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
247 Weng J, Zhou C, Zhou Q, Chen W, Yin Y, Atyah M, Dong Q, Shi Y, Ren N. Development and Validation of a Metabolic Gene-Based Prognostic Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:193-209. [PMID: 33824863 DOI: 10.2147/JHC.S300633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Krinsky G, Shanbhogue K. Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical and Imaging Implications. Radiology 2021;300:583-5. [PMID: 34227887 DOI: 10.1148/radiol.2021211316] [Reference Citation Analysis]
249 Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform 2021;22:bbaa164. [PMID: 32789496 DOI: 10.1093/bib/bbaa164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
250 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Reference Citation Analysis]
251 Nahon P, Vibert E, Nault JC, Ganne-Carrié N, Ziol M, Seror O. Optimizing curative management of hepatocellular carcinoma. Liver Int 2020;40 Suppl 1:109-15. [PMID: 32077602 DOI: 10.1111/liv.14345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
252 Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Kamimura K, Yano M. Natural regression of fibrosis in chronic hepatitis B. World J Gastroenterol 2016; 22(24): 5459-5466 [PMID: 27350724 DOI: 10.3748/wjg.v22.i24.5459] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
253 Yu Q, Dai J, Shu M. Circular RNA‐0072309 has antitumor influences in Hep3B cell line by targeting microRNA‐665. BioFactors 2020. [DOI: 10.1002/biof.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
254 Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, Lauwers GY, Odze RD, Srivastava A. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol 2018;31:989-96. [PMID: 29422640 DOI: 10.1038/s41379-018-0003-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
255 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
256 Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018;9:30869-82. [PMID: 30112114 DOI: 10.18632/oncotarget.25766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
257 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
258 Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:71-79. [PMID: 28553624 DOI: 10.2147/jhc.s105777] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
259 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
260 Li Y, Chen R, Yang J, Mo S, Quek K, Kok CH, Cheng XD, Tian S, Zhang W, Qin JJ. Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Front Genet 2020;11:814. [PMID: 32849813 DOI: 10.3389/fgene.2020.00814] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulai A, Luciani A, Zafrani ES, Bioulac-Sage P, Seror O, Imbeaud S, Zucman-Rossi J. Germline and somatic DICER1 mutations in familial and sporadic liver tumors. J Hepatol 2017;66:734-42. [PMID: 28012864 DOI: 10.1016/j.jhep.2016.12.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
262 Tsuge S, Saberi B, Cheng Y, Wang Z, Kim A, Luu H, Abraham JM, Ybanez MD, Hamilton JP, Selaru FM, Villacorta-Martin C, Schlesinger F, Philosophe B, Cameron AM, Zhu Q, Anders R, Gurakar A, Meltzer SJ. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma. Gastrointest Tumors 2019;6:11-27. [PMID: 31602373 DOI: 10.1159/000496795] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
264 Carethers JM, Braun J, Sands BE. Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology 2015;149:1131-3. [PMID: 26327133 DOI: 10.1053/j.gastro.2015.08.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
265 Huang X, Gan G, Wang X, Xu T, Xie W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 2019;15:1258-79. [PMID: 30786811 DOI: 10.1080/15548627.2019.1580105] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 19.3] [Reference Citation Analysis]
266 Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol 2018;69:1057-65. [PMID: 30030148 DOI: 10.1016/j.jhep.2018.07.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
267 Abou-Alfa GK. Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma. Lancet Oncol 2019;20:177-9. [PMID: 30665868 DOI: 10.1016/S1470-2045(19)30009-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
268 Dourthe C, Julien C, Di Tommaso S, Dupuy JW, Dugot-Senant N, Brochard A, Le Bail B, Blanc JF, Chiche L, Balabaud C, Bioulac-Sage P, Saltel F, Raymond AA. Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches. Hepatology 2021. [PMID: 33754354 DOI: 10.1002/hep.31826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Craig AJ, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova EG, Martins-Filho SN, von Felden J, Ahsen ME, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, Llovet JM, Sia D, Thung S, Losic B, Lujambio A, Villanueva A. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genet 2021;17:e1009589. [PMID: 34166362 DOI: 10.1371/journal.pgen.1009589] [Reference Citation Analysis]
270 Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, Miao H, Cui X, Wei S, Liu W, Chen S, Wang J. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci 2021;17:3608-21. [PMID: 34512169 DOI: 10.7150/ijbs.64003] [Reference Citation Analysis]
271 Minagawa T, Yamazaki K, Masugi Y, Tsujikawa H, Ojima H, Hibi T, Abe Y, Yagi H, Kitago M, Shinoda M, Itano O, Kitagawa Y, Sakamoto M. Activation of extracellular signal‐regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Hepatol Res 2020;50:353-64. [DOI: 10.1111/hepr.13445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
272 Frizziero M, McNamara MG, Lamarca A, Pihlak R, Kurup R, Hubner RA. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. Curr Med Chem 2020;27:4789-805. [PMID: 32321391 DOI: 10.2174/0929867327666200422143847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Gao DY, Ling Y, Lou XL, Wang YY, Liu LM. GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer. Oncol Lett 2018;15:3133-40. [PMID: 29435047 DOI: 10.3892/ol.2017.7695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
274 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
275 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
276 Lee HW, Park TI, Jang SY, Park SY, Park WJ, Jung SJ, Lee JH. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5766. [PMID: 28151853 DOI: 10.1097/MD.0000000000005766] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
277 Zhao Y, Yang B, Chen D, Zhou X, Wang M, Jiang J, Wei L, Chen Z. Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma. Aging (Albany NY) 2021;13:4696-712. [PMID: 33558447 DOI: 10.18632/aging.202586] [Reference Citation Analysis]
278 Bévant K, Desoteux M, Abdel Wahab AHA, Abdel Wahab SA, Metwally AM, Coulouarn C. DNA Methylation of TGFβ Target Genes: Epigenetic Control of TGFβ Functional Duality in Liver Cancer. Cells 2021;10:2207. [PMID: 34571856 DOI: 10.3390/cells10092207] [Reference Citation Analysis]
279 Muraoka M, Maekawa S, Katoh R, Komiyama Y, Nakakuki N, Takada H, Matsuda S, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamauchi K, Yamaguchi T, Nakayama Y, Inoue T, Enomoto N. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy. Hepatol Commun 2021;5:1927-38. [PMID: 34558819 DOI: 10.1002/hep4.1762] [Reference Citation Analysis]
280 Qu C, Jiao Y, Wang Y. A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals. Mol Cell Oncol 2019;6:e1614419. [PMID: 31528693 DOI: 10.1080/23723556.2019.1614419] [Reference Citation Analysis]
281 Nahm JH, Park YN. [Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:268-83. [PMID: 34824185 DOI: 10.4166/kjg.2021.140] [Reference Citation Analysis]
282 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
283 Wen L, Xin B, Wu P, Lin CH, Peng C, Wang G, Lee J, Lu LF, Feng GS. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. Hepatology 2019;69:2518-32. [PMID: 30693544 DOI: 10.1002/hep.30528] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
284 Ahmed S, Gordon L, Dueck DA, Souied O, Haider K. Current status of systemic therapy in hepatocellular cancer. Dig Liver Dis 2020:S1590-8658(20)30933-6. [PMID: 34756361 DOI: 10.1016/j.dld.2020.10.005] [Reference Citation Analysis]
285 Jin H, Wang C, Jin G, Ruan H, Gu D, Wei L, Wang H, Wang N, Arunachalam E, Zhang Y, Deng X, Yang C, Xiong Y, Feng H, Yao M, Fang J, Gu J, Cong W, Qin W. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1. Gastroenterology 2017;153:799-811.e33. [PMID: 28583823 DOI: 10.1053/j.gastro.2017.05.045] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
286 Li S, Han J, Guo G, Sun Y, Zhang T, Zhao M, Xu Y, Cui Y, Liu Y, Zhang J. Voltage-gated sodium channels β3 subunit promotes tumorigenesis in hepatocellular carcinoma by facilitating p53 degradation. FEBS Lett 2020;594:497-508. [PMID: 31626714 DOI: 10.1002/1873-3468.13641] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
287 Bárcena‐varela M, Caruso S, Llerena S, Álvarez‐sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez‐ortigosa C, Mazza G, Rombouts K, San José‐eneriz E, Rabal O, Agirre X, Iraburu M, Santos‐laso A, Banales JM, Zucman‐rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández‐barrena MG. Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology 2019;69:587-603. [DOI: 10.1002/hep.30168] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 13.0] [Reference Citation Analysis]
288 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
289 Mou H, Ozata DM, Smith JL, Sheel A, Kwan SY, Hough S, Kucukural A, Kennedy Z, Cao Y, Xue W. CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. Genome Med 2019;11:21. [PMID: 30987660 DOI: 10.1186/s13073-019-0627-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
290 Dreval K, Tryndyak V, de Conti A, Beland FA, Pogribny IP. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet 2019;10:486. [PMID: 31191608 DOI: 10.3389/fgene.2019.00486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
291 Scheiter A, Evert K, Reibenspies L, Cigliano A, Annweiler K, Müller K, Pöhmerer LM, Xu H, Cui G, Itzel T, Materna-Reichelt S, Coluccio A, Honarnejad K, Teufel A, Brochhausen C, Dombrowski F, Chen X, Evert M, Calvisi DF, Utpatel K. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. Mol Oncol 2021. [PMID: 34748271 DOI: 10.1002/1878-0261.13135] [Reference Citation Analysis]
292 Chen Y, Wang Y, Yang Y, Li Y, Wang Y, Wang G, James TD, Xuan X, Zhang H, Liu Y. A molecular-logic gate for COX-2 and NAT based on conformational and structural changes: visualizing the progression of liver disease. Chem Sci 2020;11:6209-16. [PMID: 32953015 DOI: 10.1039/d0sc00574f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 6.5] [Reference Citation Analysis]
293 Jia Y, Chen Y, Liu J. Prognosis-Predictive Signature and Nomogram Based on Autophagy-Related Long Non-coding RNAs for Hepatocellular Carcinoma. Front Genet 2020;11:608668. [PMID: 33424932 DOI: 10.3389/fgene.2020.608668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
294 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13-25. [PMID: 28647765 DOI: 10.1007/s00261-017-1209-1] [Cited by in Crossref: 159] [Cited by in F6Publishing: 153] [Article Influence: 53.0] [Reference Citation Analysis]
295 Zhou M, Yang H, Learned RM, Tian H, Ling L. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017;8:15433. [PMID: 28508871 DOI: 10.1038/ncomms15433] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 13.8] [Reference Citation Analysis]
296 Wu C, Deng L, Zhuo H, Chen X, Tan Z, Han S, Tang J, Qian X, Yao A. Circulating circRNA predicting the occurrence of hepatocellular carcinoma in patients with HBV infection. J Cell Mol Med 2020;24:10216-22. [PMID: 32692470 DOI: 10.1111/jcmm.15635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
297 Zhang Y, Liu Z, Li X, Liu L, Wang L, Han X, Li Z. Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma. Front Oncol 2021;11:732447. [PMID: 34568069 DOI: 10.3389/fonc.2021.732447] [Reference Citation Analysis]
298 Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65:1031-1042. [PMID: 27262756 DOI: 10.1016/j.jhep.2016.05.035] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 19.2] [Reference Citation Analysis]
299 Debes JD, de Knegt RJ, Boonstra A. The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals. Transplantation. 2017;101:910-915. [PMID: 28045877 DOI: 10.1097/tp.0000000000001623] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
300 Ahn KS, O'Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, Kang KJ, Roberts LR. Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma. Liver Cancer 2021;10:593-605. [PMID: 34950182 DOI: 10.1159/000516957] [Reference Citation Analysis]
301 Mani SKK, Andrisani O. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells. Genes (Basel). 2018;9:137. [PMID: 29498629 DOI: 10.3390/genes9030137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
302 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 286] [Article Influence: 89.3] [Reference Citation Analysis]
303 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
304 Sparchez Z, Mocan T. Contemporary role of liver biopsy in hepatocellular carcinoma. World J Hepatol 2018; 10(7): 452-461 [PMID: 30079131 DOI: 10.4254/wjh.v10.i7.452] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
305 Jondal DE, Thompson SM, Butters KA, Knudsen BE, Anderson JL, Carter RE, Roberts LR, Callstrom MR, Woodrum DA. Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling. Radiology 2018;288:730-8. [PMID: 29737948 DOI: 10.1148/radiol.2018172944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
306 Caruso S, O’brien DR, Cleary SP, Roberts LR, Zucman‐rossi J. Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology 2021;73:14-26. [DOI: 10.1002/hep.31394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
307 Bisso A, Filipuzzi M, Gamarra Figueroa GP, Brumana G, Biagioni F, Doni M, Ceccotti G, Tanaskovic N, Morelli MJ, Pendino V, Chiacchiera F, Pasini D, Olivero D, Campaner S, Sabò A, Amati B. Cooperation Between MYC and β-Catenin in Liver Tumorigenesis Requires Yap/Taz. Hepatology 2020;72:1430-43. [PMID: 31965581 DOI: 10.1002/hep.31120] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
308 Saillard C, Schmauch B, Laifa O, Moarii M, Toldo S, Zaslavskiy M, Pronier E, Laurent A, Amaddeo G, Regnault H, Sommacale D, Ziol M, Pawlotsky JM, Mulé S, Luciani A, Wainrib G, Clozel T, Courtiol P, Calderaro J. Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. Hepatology 2020;72:2000-13. [PMID: 32108950 DOI: 10.1002/hep.31207] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 32.0] [Reference Citation Analysis]
309 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
310 Thilakarathna WPDW, Rupasinghe HPV, Ridgway ND. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:2606. [PMID: 33807605 DOI: 10.3390/ijms22052606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Maehara J, Masugi Y, Abe T, Tsujikawa H, Kurebayashi Y, Ueno A, Ojima H, Okuda S, Jinzaki M, Shinoda M, Kitagawa Y, Oda Y, Honda H, Sakamoto M. Quantification of intratumoral collagen and elastin fibers within hepatocellular carcinoma tissues finds correlations with clinico‐patho‐radiological features. Hepatol Res 2020;50:607-19. [DOI: 10.1111/hepr.13484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
312 Huo J, Wu L, Zang Y. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma. J Cell Mol Med 2021;25:1151-65. [PMID: 33300278 DOI: 10.1111/jcmm.16181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
313 Bévant K, Coulouarn C. Landscape of genomic alterations in hepatocellular carcinoma: current knowledge and perspectives for targeted therapies. Hepatobiliary Surg Nutr 2017;6:404-7. [PMID: 29312976 DOI: 10.21037/hbsn.2017.10.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
314 Li J, Liao Y, Suo L, Zhu P, Chen X, Dang W, Liao M, Qin L, Liao W. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep 2017;7:9229. [PMID: 28835713 DOI: 10.1038/s41598-017-09696-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
315 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 16.4] [Reference Citation Analysis]
316 Yang Y, Lu Q, Shao X, Mo B, Nie X, Liu W, Chen X, Tang Y, Deng Y, Yan J. Development Of A Three-Gene Prognostic Signature For Hepatitis B Virus Associated Hepatocellular Carcinoma Based On Integrated Transcriptomic Analysis. J Cancer 2018;9:1989-2002. [PMID: 29896284 DOI: 10.7150/jca.23762] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
317 Jimenez M, Arechederra M, Ávila MA, Berasain C. Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. Transl Gastroenterol Hepatol 2018;3:84. [PMID: 30505971 DOI: 10.21037/tgh.2018.10.11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
318 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
319 Jansen PL. Fibroblast growth factor 19, a double-edged sword. Hepat Oncol 2017;4:1-4. [PMID: 30191047 DOI: 10.2217/hep-2017-0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
320 Luo LH, Jin M, Wang LQ, Xu GJ, Lin ZY, Yu DD, Yang SL, Ran RZ, Wu G, Zhang T. Long noncoding RNA TCL6 binds to miR-106a-5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathway. J Cell Physiol. 2020;235:6154-6166. [PMID: 32020591 DOI: 10.1002/jcp.29544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
321 Tang L, Zhu S, Peng W, Yin X, Tan C, Yang Y. Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma. PeerJ 2021;9:e10810. [PMID: 33604188 DOI: 10.7717/peerj.10810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res 2021;49:300060520980646. [PMID: 33567957 DOI: 10.1177/0300060520980646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
323 Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, Mukherjee SK, Thursz M, Wong CN, Sharma R, Rimassa L. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37. [PMID: 32157213 DOI: 10.1038/s41388-020-1249-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
324 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416. [PMID: 29303512 DOI: 10.1038/emm.2017.165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
325 Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology 2019;70:1262-77. [DOI: 10.1016/j.jhep.2019.01.028] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 19.7] [Reference Citation Analysis]
326 Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, Park SR, Ryoo BY. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer 2019;19:292. [PMID: 30935424 DOI: 10.1186/s12885-019-5483-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
327 De Luca E, Marino D, Di Maio M. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. Cancer Manag Res 2020;12:3721-9. [PMID: 32547208 DOI: 10.2147/CMAR.S216220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
328 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 25.0] [Reference Citation Analysis]
329 Hou D, Xiong J, Li Y, Peng Y, Xiong L. Efficacy and safety of Xiaoaiping injection for liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21993. [PMID: 32871951 DOI: 10.1097/MD.0000000000021993] [Reference Citation Analysis]
330 Li H, Guo D, Zhang Y, Yang S, Zhang R. miR-664b-5p Inhibits Hepatocellular Cancer Cell Proliferation Through Targeting Oncogene AKT2. Cancer Biother Radiopharm 2020;35:605-14. [PMID: 31967930 DOI: 10.1089/cbr.2019.3043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
332 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
333 Sia D, Llovet JM. Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2017;14:571-2. [PMID: 28765583 DOI: 10.1038/nrgastro.2017.103] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
334 Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol 2021;74:1155-66. [PMID: 33338512 DOI: 10.1016/j.jhep.2020.11.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
335 Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun 2021;27:100328. [PMID: 33549983 DOI: 10.1016/j.ctarc.2021.100328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
336 Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237-247. [PMID: 29505843 DOI: 10.1016/j.jhep.2018.02.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
337 Regel I, Eichenmüller M, Mahajan UM, Hagl B, Benitz S, Häberle B, Vokuhl C, von Schweinitz D, Kappler R. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations. J Cancer Res Clin Oncol 2020;146:1153-67. [PMID: 32189106 DOI: 10.1007/s00432-020-03182-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 2018;5:61-73. [PMID: 29984212 DOI: 10.2147/JHC.S156701] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
339 Zhang YP, Bao ZW, Wu JB, Chen YH, Chen JR, Xie HY, Zhou L, Wu J, Zheng SS. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. Technol Cancer Res Treat 2020;19:1533033820944274. [PMID: 32715976 DOI: 10.1177/1533033820944274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
341 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
342 Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 2020;139:855-63. [PMID: 32100095 DOI: 10.1007/s00439-020-02136-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
343 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
344 Hatano M, Ojima H, Masugi Y, Tsujikawa H, Hiraoka N, Kanai Y, Shimada K, Shinoda M, Sakamoto M. Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features. Hum Pathol. 2019;86:222-232. [PMID: 30597153 DOI: 10.1016/j.humpath.2018.11.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
345 Quan Y, Yang J, Qin T, Hu Y. Associations between twelve common gene polymorphisms and susceptibility to hepatocellular carcinoma: evidence from a meta-analysis. World J Surg Oncol 2019;17:216. [PMID: 31830994 DOI: 10.1186/s12957-019-1748-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
346 Kong FY, Wei X, Zhou K, Hu W, Kou YB, You HJ, Liu XM, Zheng KY, Tang RX. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLoS One 2016;11:e0158286. [PMID: 27454179 DOI: 10.1371/journal.pone.0158286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
347 Senni N, Savall M, Cabrerizo Granados D, Alves-guerra M, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 2019;68:322-34. [DOI: 10.1136/gutjnl-2017-315448] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
348 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
349 Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, Atorrasagasti C, García MG, Argemi J, Martinez ED, Mazzolini GD. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol 2019;71:78-90. [PMID: 30880225 DOI: 10.1016/j.jhep.2019.03.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
350 Lowdon RF, Wang T. Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer. PLoS One 2017;12:e0174032. [PMID: 28333948 DOI: 10.1371/journal.pone.0174032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
351 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 30.5] [Reference Citation Analysis]
352 Chen W, Desert R, Ge X, Han H, Song Z, Das S, Athavale D, You H, Nieto N. The Matrisome Genes From Hepatitis B-Related Hepatocellular Carcinoma Unveiled. Hepatol Commun 2021;5:1571-85. [PMID: 34510837 DOI: 10.1002/hep4.1741] [Reference Citation Analysis]
353 Martinez-quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology 2016;151:1192-205. [DOI: 10.1053/j.gastro.2016.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
354 Krutsenko Y, Singhi AD, Monga SP. β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers (Basel) 2021;13:1830. [PMID: 33921282 DOI: 10.3390/cancers13081830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
355 Okabe H, Yoshizumi T, Yamashita YI, Imai K, Hayashi H, Nakagawa S, Itoh S, Harimoto N, Ikegami T, Uchiyama H, Beppu T, Aishima S, Shirabe K, Baba H, Maehara Y. Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma. PLoS One 2018;13:e0203856. [PMID: 30216361 DOI: 10.1371/journal.pone.0203856] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
356 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
357 Cao DD, Xu HL, Liu L, Zheng YF, Gao SF, Xu XM, Ge W. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:44976-93. [PMID: 28402958 DOI: 10.18632/oncotarget.16689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
358 Peng H, Lu L, Zhou Z, Liu J, Zhang D, Nan K, Zhao X, Li F, Tian L, Dong H, Yao Y. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients. Genes (Basel) 2019;10:E926. [PMID: 31739500 DOI: 10.3390/genes10110926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
359 Raja A, Haq F. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. J Cancer Res Clin Oncol 2021. [PMID: 34623518 DOI: 10.1007/s00432-021-03826-w] [Reference Citation Analysis]
360 Lombardo D, Saitta C, Giosa D, Di Tocco FC, Musolino C, Caminiti G, Chines V, Franzè MS, Alibrandi A, Navarra G, Raimondo G, Pollicino T. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy. Oncol Lett 2020;19:2368-74. [PMID: 32194736 DOI: 10.3892/ol.2020.11332] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
361 Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:3682. [PMID: 30842500 DOI: 10.1038/s41598-019-39998-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
362 Kwa WT, Effendi K, Yamazaki K, Kubota N, Hatano M, Ueno A, Masugi Y, Sakamoto M. Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma. Pathol Int. 2020;70:624-632. [PMID: 32559017 DOI: 10.1111/pin.12974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
363 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
364 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 289] [Article Influence: 70.3] [Reference Citation Analysis]
365 Wang J, Huang J, Ma Q, Liu G. Association between quantitative parameters of CEUS and Sall4/Wnt/β-catenin signaling in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:3339-47. [PMID: 31114369 DOI: 10.2147/CMAR.S199968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
366 Zhang X, Li H, Mao M, Wang X, Zheng J, Yang S. Mitotically-associated long non-coding RNA promotes cancer cell proliferation in hepatocellular carcinoma by downregulating miR-122a. Oncol Lett 2019;18:6237-42. [PMID: 31788100 DOI: 10.3892/ol.2019.10947] [Reference Citation Analysis]
367 An SB, Yang K, Kim CW, Choi SH, Kim E, Kim SD, Koh JS. Longitudinal Imaging of Liver Cancer Using MicroCT and Nanoparticle Contrast Agents in CRISPR/Cas9-Induced Liver Cancer Mouse Model. Technol Cancer Res Treat 2021;20:15330338211016466. [PMID: 34039112 DOI: 10.1177/15330338211016466] [Reference Citation Analysis]
368 Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology 2016;63:1888-99. [PMID: 26844528 DOI: 10.1002/hep.28487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
369 Yamamoto M, Xin B, Watanabe K, Ooshio T, Fujii K, Chen X, Okada Y, Abe H, Taguchi Y, Miyokawa N, Furukawa H, Nishikawa Y. Oncogenic Determination of a Broad Spectrum of Phenotypes of Hepatocyte-Derived Mouse Liver Tumors. Am J Pathol 2017;187:2711-25. [PMID: 28964793 DOI: 10.1016/j.ajpath.2017.07.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
370 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
371 Choi WM, Kim JY, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Yoo C, Ryu MH, Ryoo BY, Kim KM. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int 2021;41:2189-99. [PMID: 33966338 DOI: 10.1111/liv.14932] [Reference Citation Analysis]
372 Burcu Gürdere M, Aydin A, Yencilek B, Ertürk F, Özbek O, Erkan S, Budak Y, Ceylan M. Synthesis, Antiproliferative and Cytotoxic Activities, DNA Binding Features and Molecular Docking Study of Novel Enamine Derivatives. Chem Biodivers 2020;17:e2000139. [PMID: 32374947 DOI: 10.1002/cbdv.202000139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Mittermeier C, Konopa A, Muehlich S. Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma. Cells 2020;9:E2540. [PMID: 33255630 DOI: 10.3390/cells9122540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
374 Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget 2017;8:10510-22. [PMID: 28060737 DOI: 10.18632/oncotarget.14446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
375 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
376 Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res 2018;28:690-2. [PMID: 29507396 DOI: 10.1038/s41422-018-0020-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
377 Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M, Chen X, Ganesh S, Abrams M, Monga SP. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice. Hepatology 2017;65:1581-99. [PMID: 27981621 DOI: 10.1002/hep.28975] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
378 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
379 Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, Shen ZZ, Zhang PF, Huang XY, Ke AW, Shi GM, Fan J. The long noncoding RNA NORAD enhances the TGF-β pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol 2019;234:12051-60. [PMID: 30537113 DOI: 10.1002/jcp.27869] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
380 Krautbauer S, Meier EM, Rein-Fischboeck L, Pohl R, Weiss TS, Sigruener A, Aslanidis C, Liebisch G, Buechler C. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. Biochim Biophys Acta 2016;1861:1767-74. [PMID: 27570113 DOI: 10.1016/j.bbalip.2016.08.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
381 Wu T, Dong X, Yu D, Shen Z, Yu J, Yan S. Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. Onco Targets Ther 2018;11:8633-42. [PMID: 30584322 DOI: 10.2147/OTT.S186186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
382 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
383 Song CQ, Li Y, Mou H, Moore J, Park A, Pomyen Y, Hough S, Kennedy Z, Fischer A, Yin H, Anderson DG, Conte D Jr, Zender L, Wang XW, Thorgeirsson S, Weng Z, Xue W. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. Gastroenterology 2017;152:1161-1173.e1. [PMID: 27956228 DOI: 10.1053/j.gastro.2016.12.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
384 Xing J, Bhuria V, Bui KC, Nguyen MLT, Hu Z, Hsieh CJ, Wittstein K, Stadler M, Wilkens L, Li J, Kalesse M, Bozko P, Plentz RR. Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition. Cancers (Basel) 2020;12:E615. [PMID: 32155915 DOI: 10.3390/cancers12030615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
385 Kumar R, Li DQ. PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology. Adv Cancer Res 2016;130:137-209. [PMID: 27037753 DOI: 10.1016/bs.acr.2016.01.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
386 Zhou J, Huang Z, Chen Z, Xu F, Tong R, Zheng S. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database. BMC Gastroenterol 2021;21:195. [PMID: 33931011 DOI: 10.1186/s12876-021-01786-6] [Reference Citation Analysis]
387 Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574:268-72. [PMID: 31578521 DOI: 10.1038/s41586-019-1607-3] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 27.3] [Reference Citation Analysis]
388 Serra M, Columbano A, Perra A, Kowalik MA. Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3318. [PMID: 33182674 DOI: 10.3390/cancers12113318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP. Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. Toxicol Sci 2019;170:273-82. [PMID: 31086990 DOI: 10.1093/toxsci/kfz110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
390 Peng G, Chai H, Ji W, Lu Y, Wu S, Zhao H, Li P, Hu Q. Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma. BMC Med Genomics 2021;14:150. [PMID: 34103027 DOI: 10.1186/s12920-021-00998-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
391 Tu S, Huang W, Huang C, Luo Z, Yan X. Contextual Regulation of TGF-β Signaling in Liver Cancer. Cells 2019;8:E1235. [PMID: 31614569 DOI: 10.3390/cells8101235] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
392 Desoteux M, Louis C, Bévant K, Glaise D, Coulouarn C. A Minimal Subset of Seven Genes Associated with Tumor Hepatocyte Differentiation Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5624. [PMID: 34830779 DOI: 10.3390/cancers13225624] [Reference Citation Analysis]
393 Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Reference Citation Analysis]
394 Guégan JP, Lapouge M, Voisin L, Saba-El-Leil MK, Tanguay PL, Lévesque K, Brégeon J, Mes-Masson AM, Lamarre D, Haibe-Kains B, Trinh VQ, Soucy G, Bilodeau M, Meloche S. Signaling by the tyrosine kinase Yes promotes liver cancer development. Sci Signal 2022;15:eabj4743. [PMID: 35041461 DOI: 10.1126/scisignal.abj4743] [Reference Citation Analysis]
395 Dos Santos ML, França A, Lima Filho ACM, Florentino RM, Diniz PH, Oliveira Lemos F, Gonçalves CAX, Coelho VL, Lima CX, Foureaux G, Nathanson MH, Vidigal PVT, Leite MF. Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma. Oncol Lett 2022;23:32. [PMID: 34966448 DOI: 10.3892/ol.2021.13150] [Reference Citation Analysis]
396 Chiu DK, Yuen VW, Cheu JW, Wei LL, Ting V, Fehlings M, Sumatoh H, Nardin A, Newell EW, Ng IO, Yau TC, Wong CM, Wong CC. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology. 2020;159:609-623. [PMID: 32275969 DOI: 10.1053/j.gastro.2020.03.074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
397 Savall M, Senni N, Lagoutte I, Sohier P, Dentin R, Romagnolo B, Perret C, Bossard P. Cooperation Between the NRF2 Pathway and Oncogenic β-catenin During HCC Tumorigenesis. Hepatol Commun 2021;5:1490-506. [PMID: 34510835 DOI: 10.1002/hep4.1746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Nault J, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie‐bergman C, Ziol M, Bioulac‐sage P, Couchy G, Blanc J, Nahon P, Amaddeo G, Ganne‐carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman‐rossi J. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology 2020;71:164-82. [DOI: 10.1002/hep.30811] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
399 de Campos PB, Oliveira CP, Stefano JT, Martins-Filho SN, Chagas AL, Herman P, D'Albuquerque LC, Alvares-da-Silva MR, Longatto-Filho A, Carrilho FJ, Alves VAF. Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype. Histol Histopathol 2020;35:729-40. [PMID: 31858523 DOI: 10.14670/HH-18-194] [Reference Citation Analysis]
400 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
401 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
402 D'Avola D, Bilbao JI, Sangro B. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. Cardiovasc Intervent Radiol 2019;42:1262-70. [PMID: 31069465 DOI: 10.1007/s00270-019-02221-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
403 Zhang L, Xia W, Yan ZP, Sun JH, Zhong BY, Hou ZH, Yang MJ, Zhou GH, Wang WS, Zhao XY, Jian JM, Huang P, Zhang R, Zhang S, Zhang JY, Li Z, Zhu XL, Gao X, Ni CF. Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. Front Oncol. 2020;10:593292. [PMID: 33102242 DOI: 10.3389/fonc.2020.593292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
404 Lambrecht C, Ferreira GB, Omella JD, Libbrecht L, DE Vos R, Derua R, Mathieu C, Overbergh L, Waelkens E, Janssens V. Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers. Cancer Genomics Proteomics 2020;17:669-85. [PMID: 33099469 DOI: 10.21873/cgp.20222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Wu C, Tang G, Wang X, Zhang J, Chen S, Lu C, Zhang D, Li Y. Micro-RNA-21 rs1292037 A>G polymorphism can predict hepatocellular carcinoma prognosis (HCC), and plays a key role in cell proliferation and ischemia-reperfusion injury (IRI) in HCC cell model of IRI. Saudi Med J 2020;41:383-92. [PMID: 32291425 DOI: 10.15537/smj.2020.4.24994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
406 Saidak Z, Giacobbi A, Louandre C, Sauzay C, Mammeri Y, Galmiche A. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. Cancer Letters 2017;392:1-8. [DOI: 10.1016/j.canlet.2017.01.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
407 Fang L, Gao C, Bai R, Wang H, Du S. Overexpressed sFRP3 exerts an inhibitory effect on hepatocellular carcinoma via inactivation of the Wnt/β-catenin signaling pathway. Cancer Gene Ther 2021;28:875-91. [DOI: 10.1038/s41417-020-0201-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
408 Schulte LA, López-Gil JC, Sainz B Jr, Hermann PC. The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E684. [PMID: 32183251 DOI: 10.3390/cancers12030684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
409 Nahon P, Allaire M, Nault JC, Paradis V. Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepat Oncol 2020;7:HEP36. [PMID: 33680428 DOI: 10.2217/hep-2020-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
410 Macek Jilkova Z, Kurma K, Decaens T. Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment. Cancers (Basel) 2019;11:E1487. [PMID: 31581753 DOI: 10.3390/cancers11101487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
411 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Huang A, Zhao X, Yang XR, Li FQ, Zhou XL, Wu K, Zhang X, Sun QM, Cao Y, Zhu HM, Wang XD, Yang HM, Wang J, Tang ZY, Hou Y, Fan J, Zhou J. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017;67:293-301. [PMID: 28323123 DOI: 10.1016/j.jhep.2017.03.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
413 Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169:1327-1341.e23. [PMID: 28622513 DOI: 10.1016/j.cell.2017.05.046] [Cited by in Crossref: 846] [Cited by in F6Publishing: 791] [Article Influence: 169.2] [Reference Citation Analysis]
414 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
415 Halgand B, Desterke C, Rivière L, Fallot G, Sebagh M, Calderaro J, Bioulac-Sage P, Neuveut C, Buendia MA, Samuel D, Féray C. Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant. Hepatology 2018;67:86-96. [PMID: 28802063 DOI: 10.1002/hep.29463] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
416 Xu W, Yu J, Wong VW. Mechanism and prediction of HCC development in HBV infection. Best Practice & Research Clinical Gastroenterology 2017;31:291-8. [DOI: 10.1016/j.bpg.2017.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
417 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
418 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
419 Yim SY, Kang SH, Shin JH, Jeong YS, Sohn BH, Um SH, Lee JS. Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cells 2020;9:E2002. [PMID: 32878261 DOI: 10.3390/cells9092002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
420 Li MM, Tang YQ, Gong YF, Cheng W, Li HL, Kong FE, Zhu WJ, Liu SS, Huang L, Guan XY, Ma NF, Liu M. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC Cancer 2019;19:851. [PMID: 31462277 DOI: 10.1186/s12885-019-6041-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
421 Paşcalău V, Tertis M, Pall E, Suciu M, Marinca T, Pustan M, Merie V, Rus I, Moldovan C, Topala T, Pavel C, Popa C. Bovine serum albumin gel/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery. J Appl Polym Sci 2020;137:49002. [DOI: 10.1002/app.49002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
422 Lei GL, Niu Y, Cheng SJ, Li YY, Bai ZF, Yu LX, Hong ZX, Liu H, Liu HH, Yan J, Gao Y, Zhang SG, Chen Z, Li RS, Yang PH. Upregulation of long noncoding RNA W42 promotes tumor development by binding with DBN1 in hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2586-2602 [PMID: 34092977 DOI: 10.3748/wjg.v27.i20.2586] [Reference Citation Analysis]
423 Zheng BH, Ma JQ, Tian LY, Dong LQ, Song GH, Pan JM, Liu YM, Yang SX, Wang XY, Zhang XM, Zhou J, Fan J, Shi JY, Gao Q. The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med 2020;10:45-56. [PMID: 32508015 DOI: 10.1002/ctm2.11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
424 Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152:745-761. [PMID: 28043904 DOI: 10.1053/j.gastro.2016.11.048] [Cited by in Crossref: 373] [Cited by in F6Publishing: 376] [Article Influence: 62.2] [Reference Citation Analysis]
425 Batur T, Argundogan A, Keles U, Mutlu Z, Alotaibi H, Senturk S, Ozturk M. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. Int J Mol Sci 2021;22:13247. [PMID: 34948046 DOI: 10.3390/ijms222413247] [Reference Citation Analysis]
426 Yan Y, Luo YH, Zheng DF, Mu T, Wu ZJ. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:34-45. [PMID: 32563589 DOI: 10.1016/j.hbpd.2020.05.002] [Reference Citation Analysis]
427 Arechederra M, Daian F, Yim A, Bazai SK, Richelme S, Dono R, Saurin AJ, Habermann BH, Maina F. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat Commun 2018;9:3164. [PMID: 30089774 DOI: 10.1038/s41467-018-05550-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 15.3] [Reference Citation Analysis]
428 Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory Mechanisms of HCC Development. Cancers (Basel) 2020;12:E641. [PMID: 32164265 DOI: 10.3390/cancers12030641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
429 Si T, Huang Z, Jiang Y, Walker-Jacobs A, Gill S, Hegarty R, Hamza M, Khorsandi SE, Jassem W, Heaton N, Ma Y. Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity. Front Oncol 2021;11:738841. [PMID: 34660300 DOI: 10.3389/fonc.2021.738841] [Reference Citation Analysis]
430 Bouzas Muñoz A, Giménez-Bastida JA, Tejedor AG, Haros CM, Gómez de Cedrón M, Ramírez de Molina A, Laparra Llopis JM. Intestinal Intervention Strategy Targeting Myeloid Cells to Improve Hepatic Immunity during Hepatocarcinoma Development. Biomedicines 2021;9:1633. [PMID: 34829862 DOI: 10.3390/biomedicines9111633] [Reference Citation Analysis]
431 Chen W, Bi K, Zhang X, Jiang J, Diao H. In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020;3:100067. [PMID: 33073226 DOI: 10.1016/j.jtauto.2020.100067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
432 Bergquist JR, Li AY, Javadi CS, Chima RS, Frye JS, Visser BC. Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus. Dig Dis Sci 2021;66:1797-801. [PMID: 33140182 DOI: 10.1007/s10620-020-06682-9] [Reference Citation Analysis]
433 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
434 Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma. Lancet 2017;389:4-6. [PMID: 27932228 DOI: 10.1016/S0140-6736(16)32480-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
435 Meng J, Wang L, Hou J, Yang X, Lin K, Nan H, Li M, Wu X, Chen X. CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop. Cancer Sci 2021;112:3099-110. [PMID: 34050704 DOI: 10.1111/cas.14995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J, Peng M, Guo Y, Wen Z. Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2019;2019:2408348. [PMID: 31828095 DOI: 10.1155/2019/2408348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
437 Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, Nie Z, Yin J. LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep 2019;39:BSR20190251. [PMID: 30910841 DOI: 10.1042/BSR20190251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
438 Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med 2020;20:329-37. [PMID: 32239299 DOI: 10.1007/s10238-020-00620-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
439 Ding K, Liao Y, Gong D, Zhao X, Ji W. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2018;502:194-201. [DOI: 10.1016/j.bbrc.2018.05.143] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
440 Wang BG, Jiang LY, Xu Q. Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis. Biosci Rep 2018;38:BSR20180712. [PMID: 29976775 DOI: 10.1042/BSR20180712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
441 Jeon J, Maeng LS, Bae YJ, Lee EJ, Yoon YC, Yoon N. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. Cancer Genomics Proteomics 2018;15:291-8. [PMID: 29976634 DOI: 10.21873/cgp.20087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
442 Nacer DF, Liljedahl H, Karlsson A, Lindgren D, Staaf J. Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor. Brief Bioinform 2021:bbab154. [PMID: 33971670 DOI: 10.1093/bib/bbab154] [Reference Citation Analysis]
443 Lee YT, Sun N, Kim M, Wang JJ, Tran BV, Zhang RY, Qi D, Zhang C, Chen PJ, Sadeghi S, Finn RS, Saab S, Han SB, Busuttil RW, Pei R, Zhu Y, Tseng HR, You S, Yang JD, Agopian VG. Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. Liver Transpl 2021. [PMID: 34664394 DOI: 10.1002/lt.26337] [Reference Citation Analysis]
444 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
445 Liu Q, Zhou B, Liao R, Zhou X, Yan X. PIAS4, upregulated in hepatocellular carcinoma, promotes tumorigenicity and metastasis. J Cell Biochem 2020;121:3372-81. [PMID: 31943317 DOI: 10.1002/jcb.29610] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
446 Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy CA, Lee C, Moore DD, Fu L. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. Cancer Cell 2016;30:909-24. [PMID: 27889186 DOI: 10.1016/j.ccell.2016.10.007] [Cited by in Crossref: 190] [Cited by in F6Publishing: 168] [Article Influence: 31.7] [Reference Citation Analysis]
447 Allaire M, Nault JC. Type 2 diabetes-associated hepatocellular carcinoma: A molecular profile. Clin Liver Dis (Hoboken) 2016;8:53-8. [PMID: 31041063 DOI: 10.1002/cld.569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
448 Yen CH, Lai CC, Shia TH, Chen M, Yu HC, Liu YP, Chang FR. Gynura divaricata attenuates tumor growth and tumor relapse after cisplatin therapy in HCC xenograft model through suppression of cancer stem cell growth and Wnt/β-catenin signalling. J Ethnopharmacol 2018;213:366-75. [PMID: 28729225 DOI: 10.1016/j.jep.2017.07.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
449 Nahon P, Nault J. Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. Liver Int 2017;37:1591-601. [DOI: 10.1111/liv.13419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
450 de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA, Pogribny IP. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 2017;8:88517-88528. [PMID: 29179453 DOI: 10.18632/oncotarget.19774] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
451 Liu Q, Fan D, Adah D, Wu Z, Liu R, Yan QT, Zhang Y, Du ZY, Wang D, Li Y, Bao SY, Liu LP. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma. Oncol Rep 2018;40:2547-57. [PMID: 30226584 DOI: 10.3892/or.2018.6667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
452 Cerapio JP, Marchio A, Cano L, López I, Fournié JJ, Régnault B, Casavilca-Zambrano S, Ruiz E, Dejean A, Bertani S, Pineau P. Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry. Oncotarget 2021;12:475-92. [PMID: 33747361 DOI: 10.18632/oncotarget.27890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
453 Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. Oncotarget 2018;9:21844-60. [PMID: 29774107 DOI: 10.18632/oncotarget.25074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
454 Cao SW, Huang JL, Chen J, Hu YW, Hu XM, Ren TY, Zheng SH, Lin JD, Tang J, Zheng L, Wang Q. Long non-coding RNA UBE2CP3 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 2017;8:65370-85. [PMID: 29029437 DOI: 10.18632/oncotarget.18524] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
455 Wu M, Luo J, Wang W, Chang T, Hwang W, Lee K, Liu S, Yang J, Chiou C, Chang C, Chiang W. Risk analysis of malignant potential of oral verrucous hyperplasia: A follow-up study of 269 patients and copy number variation analysis. Head & Neck 2018;40:1046-56. [DOI: 10.1002/hed.25076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
456 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
457 Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, Zhan P, Chen J, Shen S, Guo H, Zhang M, Wang Y, Zhang F, Zhang W, Xiao J, Kong B, Friess H, Zhuge Y, Yan H, Zou X. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway. Mol Carcinog 2018;57:201-15. [PMID: 29027712 DOI: 10.1002/mc.22747] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
458 Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci U S A 2020;117:6103-13. [PMID: 32123069 DOI: 10.1073/pnas.1912146117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
459 Wang Y, Wang X, Huang X, Zhang J, Hu J, Qi Y, Xiang B, Wang Q. Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis. J Cancer 2021;12:2993-3010. [PMID: 33854600 DOI: 10.7150/jca.56005] [Reference Citation Analysis]
460 Gruttadauria S, Barbera F, Conaldi PG, Pagano D, Liotta R, Gringeri E, Miraglia R, Burgio G, Barbara M, Pietrosi G, Cammà C, Di Francesco F. Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection. Cancers (Basel) 2021;13:518. [PMID: 33572904 DOI: 10.3390/cancers13030518] [Reference Citation Analysis]
461 Kieckhaefer JE, Maina F, Wells RG, Wangensteen KJ. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. Semin Liver Dis 2019;39:261-74. [PMID: 30912094 DOI: 10.1055/s-0039-1678725] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
462 Montagner A, Le Cam L, Guillou H. β-catenin oncogenic activation rewires fatty acid catabolism to fuel hepatocellular carcinoma. Gut 2019;68:183-5. [PMID: 30077995 DOI: 10.1136/gutjnl-2018-316557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
463 Yu J, Yuan X, Sjöholm L, Liu T, Kong F, Ekström TJ, Björkholm M, Xu D. Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma. Cancer Lett 2018;434:33-41. [PMID: 30017965 DOI: 10.1016/j.canlet.2018.07.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
464 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
465 Barone M, Di Leo A, Sabbà C, Mazzocca A. The perplexity of targeting genetic alterations in hepatocellular carcinoma. Med Oncol 2020;37:67. [PMID: 32699957 DOI: 10.1007/s12032-020-01392-8] [Reference Citation Analysis]
466 Labgaa I, Taffé P, Martin D, Clerc D, Schwartz M, Kokudo N, Denys A, Halkic N, Demartines N, Melloul E. Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:138-47. [PMID: 32399428 DOI: 10.1159/000505093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
467 Tang C, Ma J, Liu X, Liu Z. Identification of a prognostic signature of nine metabolism-related genes for hepatocellular carcinoma. PeerJ 2020;8:e9774. [PMID: 32953265 DOI: 10.7717/peerj.9774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
468 Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, Chen Z, Shao J. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem 2019;179:916-35. [PMID: 31306818 DOI: 10.1016/j.ejmech.2019.06.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
469 Cadoux M, Caruso S, Pham S, Gougelet A, Pophillat C, Riou R, Loesch R, Colnot S, Nguyen CT, Calderaro J, Celton-morizur S, Guerra N, Zucman-rossi J, Desdouets C, Couty J. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology 2021;74:1386-97. [DOI: 10.1016/j.jhep.2021.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
470 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
471 Yang S, Cai H, Hu B, Tu J. LncRNA SAMMSON negatively regulates miR-9-3p in hepatocellular carcinoma cells and has prognostic values. Biosci Rep 2019;39:BSR20190615. [PMID: 31164410 DOI: 10.1042/BSR20190615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
472 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
473 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, Ahsen ME, von Felden J, Labgaa I, DʹAvola D, Allette K, Lira SA, Furtado GC, Garcia-Lezana T, Restrepo P, Stueck A, Ward SC, Fiel MI, Hiotis SP, Gunasekaran G, Sia D, Schadt EE, Sebra R, Schwartz M, Llovet JM, Thung S, Stolovitzky G, Villanueva A. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun 2020;11:291. [PMID: 31941899 DOI: 10.1038/s41467-019-14050-z] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 34.0] [Reference Citation Analysis]
475 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
476 Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, Cao Y, Ozata DM, Mou H, Yin H, Weng Z, Wang XW, Xue W. Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. Hepatology 2020;71:275-90. [PMID: 31188495 DOI: 10.1002/hep.30807] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
477 Erkizan HV, Sukhadia S, Natarajan TG, Marino G, Notario V, Lichy JH, Wadleigh RG. Exome sequencing identifies novel somatic variants in African American esophageal squamous cell carcinoma. Sci Rep 2021;11:14814. [PMID: 34285259 DOI: 10.1038/s41598-021-94064-0] [Reference Citation Analysis]
478 Jang JW, Kim HS, Kim JS, Lee SK, Han JW, Sung PS, Bae SH, Choi JY, Yoon SK, Han DJ, Kim TM, Roberts LR. Distinct Patterns of HBV Integration and TERT Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma. Int J Mol Sci 2021;22:7056. [PMID: 34209079 DOI: 10.3390/ijms22137056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
479 Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun 2018;9:5235. [PMID: 30531861 DOI: 10.1038/s41467-018-07552-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
480 Graham RP, Terracciano LM, Meves A, Vanderboom PM, Dasari S, Yeh MM, Torbenson MS, Cruise MW. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss. Mod Pathol 2016;29:607-15. [DOI: 10.1038/modpathol.2016.59] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
481 Li J, Zhao X, Wang D, He W, Zhang S, Cao W, Huang Y, Wang L, Zhou S, Luo K. Up-regulated expression of phospholipase C, β1 is associated with tumor cell proliferation and poor prognosis in hepatocellular carcinoma. Onco Targets Ther 2016;9:1697-706. [PMID: 27051304 DOI: 10.2147/OTT.S97189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
482 Ozcan M, Altay O, Lam S, Turkez H, Aksoy Y, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach. Adv Biosyst 2020;4:e2000030. [PMID: 32529800 DOI: 10.1002/adbi.202000030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
483 Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel) 2021;13:4550. [PMID: 34572776 DOI: 10.3390/cancers13184550] [Reference Citation Analysis]
484 Luo D, Hou D, Wen T, Feng M, Zhang H. Efficacy and safety of Brucea javanica oil emulsion for liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23197. [PMID: 33217831 DOI: 10.1097/MD.0000000000023197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 2018;9:4962. [PMID: 30470740 DOI: 10.1038/s41467-018-07338-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
486 Ziv E, Zhang Y, Kelly L, Nikolovski I, Boas FE, Erinjeri JP, Cai L, Petre EN, Brody LA, Covey AM, Getrajdman G, Harding JJ, Sofocleous C, Abou-Alfa GK, Solomon SB, Brown KT, Yarmohammadi H. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology 2020;297:225-34. [PMID: 32780006 DOI: 10.1148/radiol.2020200201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
487 Connor F, Rayner TF, Aitken SJ, Feig C, Lukk M, Santoyo-Lopez J, Odom DT. Mutational landscape of a chemically-induced mouse model of liver cancer. J Hepatol. 2018;69:840-850. [PMID: 29958939 DOI: 10.1016/j.jhep.2018.06.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
488 Montironi C, Montal R, Llovet JM. New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:56-61. [PMID: 31508221 DOI: 10.1002/cld.796] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
489 Hou Y, Wang Z, Huang S, Sun C, Zhao J, Shi J, Li Z, Wang Z, He X, Tam NL, Wu L. SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma. Cell Death Dis 2019;10:929. [PMID: 31804459 DOI: 10.1038/s41419-019-2163-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
490 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
491 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
492 Cheng S, Li T, Wang C, Wang K, Lai C, Yan J, Fan H, Sun F, Wang Z, Zhang P, Yu L, Hong Z, Lei G, Sun B, Gao Y, Xiao Z, Ji X, Wang R, Wu J, Wang X, Zhang S, Yang P. Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma. Oncotarget. 2018;9:36057-36066. [PMID: 30546827 DOI: 10.18632/oncotarget.23282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
493 Pillai A, Ahn J, Kulik L. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol 2020;115:1960-9. [PMID: 33038134 DOI: 10.14309/ajg.0000000000000843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
494 Sun Y, Li W, Shen S, Yang X, Lu B, Zhang X, Lu P, Shen Y, Ji J. Loss of alanine-glyoxylate and serine-pyruvate aminotransferase expression accelerated the progression of hepatocellular carcinoma and predicted poor prognosis. J Transl Med 2019;17:390. [PMID: 31771612 DOI: 10.1186/s12967-019-02138-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
495 Moreno FS, Heidor R, Pogribny IP. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and Cancer 2016;68:719-33. [DOI: 10.1080/01635581.2016.1180410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
496 Zheng Q, Zhao J, Yu H, Zong H, He X, Zhao Y, Li Y, Wang Y, Bao Y, Li Y, Chen B, Guo W, Wang Y, Chen Z, Zhao Y, Wang L, He X, Huang S. Tumor‐Specific Transcripts Are Frequently Expressed in Hepatocellular Carcinoma With Clinical Implication and Potential Function. Hepatology 2020;71:259-74. [DOI: 10.1002/hep.30805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
497 Martins-filho SN, Alves VAF. The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. Surg Exp Pathol 2019;2. [DOI: 10.1186/s42047-019-0047-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
498 Caruso S, Nault JC. A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma. Gastroenterology 2019;157:1477-9. [PMID: 31606468 DOI: 10.1053/j.gastro.2019.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Alnuqaydan AM, Rah B. Tamarix articulata Inhibits Cell Proliferation, Promotes Cell Death Mechanisms and Triggers G0/G1 Cell Cycle Arrest in Hepatocellular Carcinoma Cells. Food Technol Biotechnol 2021;59:162-73. [PMID: 34316277 DOI: 10.17113/ftb.59.02.21.6904] [Reference Citation Analysis]
500 Mulé S, Galletto Pregliasco A, Tenenhaus A, Kharrat R, Amaddeo G, Baranes L, Laurent A, Regnault H, Sommacale D, Djabbari M, Pigneur F, Tacher V, Kobeiter H, Calderaro J, Luciani A. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. Radiology 2020;295:562-71. [PMID: 32228294 DOI: 10.1148/radiol.2020192230] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
501 Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells 2021;10:648. [PMID: 33804045 DOI: 10.3390/cells10030648] [Reference Citation Analysis]
502 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
503 Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017;67:1074-1083. [PMID: 28733222 DOI: 10.1016/j.jhep.2017.07.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
504 Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63-101. [PMID: 33579428 DOI: 10.1016/bs.acr.2020.10.002] [Reference Citation Analysis]
505 Liu Y, Qi X, Zeng Z, Wang L, Wang J, Zhang T, Xu Q, Shen C, Zhou G, Yang S, Chen X, Lu F. CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Sci Rep 2017;7:2796. [PMID: 28584302 DOI: 10.1038/s41598-017-03070-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
506 Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019;10:4018-4025. [PMID: 31258846 DOI: 10.18632/oncotarget.26998] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
507 Tan J, Song M, Zhou M, Hu Y. Antibiotic tigecycline enhances cisplatin activity against human hepatocellular carcinoma through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun 2017;483:17-23. [PMID: 28069382 DOI: 10.1016/j.bbrc.2017.01.021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
508 Qiu Z, Zou K, Zhuang L, Qin J, Li H, Li C, Zhang Z, Chen X, Cen J, Meng Z, Zhang H, Li Y, Hui L. Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Sci Rep 2016;6:27411. [PMID: 27273737 DOI: 10.1038/srep27411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
509 Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang JS. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol 2018;33:475-83. [PMID: 28612951 DOI: 10.1111/jgh.13848] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
510 Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep 2020;2:100167. [PMID: 33134907 DOI: 10.1016/j.jhepr.2020.100167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
511 Wang R, Jiao Y, Li Y, Ye S, Pan G, Qin S, Hua F, Liu Y. The Prediction and Prognostic Significance of INPP5K Expression in Patients with Liver Cancer. Biomed Res Int 2020;2020:9519235. [PMID: 32420386 DOI: 10.1155/2020/9519235] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
512 Howell JA, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumor DNA in gastrointestinal malignancy. Translational Research 2017;183:137-54. [DOI: 10.1016/j.trsl.2016.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
513 Huang S, Li J, Tam NL, Sun C, Hou Y, Hughes B, Wang Z, Zhou Q, He X, Wu L. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness. Mol Carcinog 2019;58:603-15. [PMID: 30556610 DOI: 10.1002/mc.22954] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
514 Liu Q, Chen L, Yin W, Nie Y, Zeng P, Yang X. Anti-tumor effect of ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis. Cell Cycle 2021;:1-12. [PMID: 34878966 DOI: 10.1080/15384101.2021.1995684] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, Weiss MJ, He J, Philosophe B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight 2021;6:138197. [PMID: 34003798 DOI: 10.1172/jci.insight.138197] [Reference Citation Analysis]
516 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
517 Xie K, Xu L, Wu H, Liao H, Luo L, Liao M, Gong J, Deng Y, Yuan K, Wu H, Zeng Y. OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis. Oncoimmunology 2018;7:e1404214. [PMID: 29632718 DOI: 10.1080/2162402X.2017.1404214] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
518 Lin Z, Xu SH, Wang HQ, Cai YJ, Ying L, Song M, Wang YQ, Du SJ, Shi KQ, Zhou MT. Prognostic value of DNA repair based stratification of hepatocellular carcinoma. Sci Rep. 2016;6:25999. [PMID: 27174663 DOI: 10.1038/srep25999] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
519 Zhu AX, Kang Y, Yen C, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau K, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart J, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019;20:282-96. [DOI: 10.1016/s1470-2045(18)30937-9] [Cited by in Crossref: 473] [Cited by in F6Publishing: 294] [Article Influence: 157.7] [Reference Citation Analysis]
520 Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MTS, Wong J, Yeung PC, Lai PBS, Chen Z, Jin H, Chen J, Chan SL, Chan AWH, To KF, Sung JJY, Chen M, Cheng AS. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019;. [PMID: 31076403 DOI: 10.1136/gutjnl-2018-317257] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
521 Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, Albuquerque M, Couchy G, Paradis V, Couty JP, Zucman-Rossi J, Desdouets C. Polyploidy spectrum: a new marker in HCC classification. Gut 2020;69:355-64. [PMID: 30979717 DOI: 10.1136/gutjnl-2018-318021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
522 Rajan PK, Udoh UA, Sanabria JD, Banerjee M, Smith G, Schade MS, Sanabria J, Sodhi K, Pierre S, Xie Z, Shapiro JI, Sanabria J. The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8894. [PMID: 33255318 DOI: 10.3390/ijms21238894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
523 Rice A, Del Rio Hernandez A. The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Front Oncol 2019;9:952. [PMID: 31608239 DOI: 10.3389/fonc.2019.00952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
524 Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol 2021. [PMID: 34863035 DOI: 10.1002/1878-0261.13154] [Reference Citation Analysis]
525 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Reference Citation Analysis]
526 Cao D, Cai C, Ye M, Gong J, Wang M, Li J, Gong J. Differential metabonomic profiles of primary hepatocellular carcinoma tumors from alcoholic liver disease, HBV-infected, and HCV-infected cirrhotic patients. Oncotarget 2017;8:53313-25. [PMID: 28881813 DOI: 10.18632/oncotarget.18397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
527 Li J, Zhou J, Kai S, Wang C, Wang D, Jiang J. Network-Based Coexpression Analysis Identifies Functional and Prognostic Long Noncoding RNAs in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1371632. [PMID: 33083449 DOI: 10.1155/2020/1371632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
528 Sun T, Mao W, Peng H, Wang Q, Jiao L. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cell Oncol (Dordr) 2021;44:689-99. [PMID: 33655469 DOI: 10.1007/s13402-021-00595-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
529 Huo J, Wu L, Zang Y. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma. Med Sci Monit 2020;26:e925494. [PMID: 32945289 DOI: 10.12659/MSM.925494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
530 Salazar J, Le A. The Heterogeneity of Liver Cancer Metabolism. Adv Exp Med Biol 2021;1311:127-36. [PMID: 34014539 DOI: 10.1007/978-3-030-65768-0_9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
531 Gérard C, Di-Luoffo M, Gonay L, Caruso S, Couchy G, Loriot A, Castven D, Tao J, Konobrocka K, Cordi S, Monga SP, Hanert E, Marquardt JU, Zucman-Rossi J, Lemaigre FP. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. J Hepatol 2019;71:323-32. [PMID: 30953666 DOI: 10.1016/j.jhep.2019.03.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
532 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
533 Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology 2019;157:807-22. [PMID: 31194980 DOI: 10.1053/j.gastro.2019.05.069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
534 Ben-moshe S, Itzkovitz S. Spatial heterogeneity in the mammalian liver. Nat Rev Gastroenterol Hepatol 2019;16:395-410. [DOI: 10.1038/s41575-019-0134-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 23.7] [Reference Citation Analysis]
535 Ezzoukhry Z, Henriet E, Piquet L, Boyé K, Bioulac-sage P, Balabaud C, Couchy G, Zucman-rossi J, Moreau V, Saltel F. TGF-β1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking. European Journal of Cell Biology 2016;95:503-12. [DOI: 10.1016/j.ejcb.2016.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
536 Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
537 Grossi I, Arici B, Portolani N, De Petro G, Salvi A. Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma. Oncotarget 2017;8:6955-69. [PMID: 28036298 DOI: 10.18632/oncotarget.14332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
538 Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers (Basel) 2021;13:3633. [PMID: 34298844 DOI: 10.3390/cancers13143633] [Reference Citation Analysis]
539 Yu QJ, Liang YZ, Mei XP, Fang TY. Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma. EXCLI J 2020;19:861-71. [PMID: 32665773 DOI: 10.17179/excli2020-1224] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
540 Zhou Y, Wang L, Zhang W, Ma J, Zhang Z, Yang M, Yu J, Luo J, Yan Z, Xu Y. Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/6335155] [Reference Citation Analysis]
541 Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016;65:663-665. [PMID: 27417216 DOI: 10.1016/j.jhep.2016.07.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 12.5] [Reference Citation Analysis]
542 Chava S, Lee C, Aydin Y, Chandra PK, Dash A, Chedid M, Thung SN, Moroz K, Wu T, Nayak NC, Dash S. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. Oncotarget 2017;8:40019-36. [PMID: 28402954 DOI: 10.18632/oncotarget.16685] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
543 Deng H, Shang W, Lu G, Guo P, Ai T, Fang C, Tian J. Targeted and Multifunctional Technology for Identification between Hepatocellular Carcinoma and Liver Cirrhosis. ACS Appl Mater Interfaces 2019;11:14526-37. [PMID: 30776888 DOI: 10.1021/acsami.8b20600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
544 Shi M, Li ZY, Zhang LM, Wu XY, Xiang SH, Wang YG, Zhang YQ. Hsa_circ_0007456 regulates the natural killer cell-mediated cytotoxicity toward hepatocellular carcinoma via the miR-6852-3p/ICAM-1 axis. Cell Death Dis 2021;12:94. [PMID: 33462208 DOI: 10.1038/s41419-020-03334-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
545 Péneau C, Zucman-Rossi J, Nault JC. Genomics of Viral Hepatitis-Associated Liver Tumors. J Clin Med 2021;10:1827. [PMID: 33922394 DOI: 10.3390/jcm10091827] [Reference Citation Analysis]
546 Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, Wang P, Qin J, Zhuang L, Wang W, Xie F, Gu Y, Zou K, Li C, Li C, Wang C, Cen J, Chen X, Shu Y, Zhang Z, Sun L, Min L, Fu Y, Huang X, Lv H, Zhou H, Ji Y, Zhang Z, Meng Z, Shi X, Zhang H, Li Y, Hui L. A Pharmacogenomic Landscape in Human Liver Cancers. Cancer Cell 2019;36:179-193.e11. [PMID: 31378681 DOI: 10.1016/j.ccell.2019.07.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
547 Akhdar H, El Shamieh S, Musso O, Désert R, Joumaa W, Guyader D, Aninat C, Corlu A, Morel F. The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals. PLoS One 2016;11:e0167543. [PMID: 27936036 DOI: 10.1371/journal.pone.0167543] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
548 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [PMID: 34904043 DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
549 Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 2022;14:1. [PMID: 34986867 DOI: 10.1186/s13073-021-00995-8] [Reference Citation Analysis]
550 Tang Y, Chen J, Li J, Zheng Y, Zhong X, Huang S, Chen B, Peng B, Zou X, Chen X. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. Phytomedicine 2021;86:153563. [PMID: 33951569 DOI: 10.1016/j.phymed.2021.153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
551 Brar TS, Hilgenfeldt E, Soldevila-pico C. Etiology and Pathogenesis of Hepatocellular Carcinoma. In: Liu C, editor. Precision Molecular Pathology of Liver Cancer. Cham: Springer International Publishing; 2018. pp. 1-15. [DOI: 10.1007/978-3-319-68082-8_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
552 Piorońska W, Nwosu ZC, Han M, Büttner M, Ebert MP, Dooley S, Meyer C. Dysregulated paired related homeobox 1 impacts on hepatocellular carcinoma phenotypes. BMC Cancer 2021;21:1006. [PMID: 34496784 DOI: 10.1186/s12885-021-08637-3] [Reference Citation Analysis]
553 Pellegrino R, Thavamani A, Calvisi DF, Budczies J, Neumann A, Geffers R, Kroemer J, Greule D, Schirmacher P, Nordheim A, Longerich T. Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC. Cancers (Basel) 2021;13:E199. [PMID: 33429878 DOI: 10.3390/cancers13020199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Wang SJ, Yang PM. A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma. J Pers Med 2021;11:332. [PMID: 33922244 DOI: 10.3390/jpm11050332] [Reference Citation Analysis]
555 Chen H, Yuan J, Hao J, Wen Y, Lv Y, Chen L, Yang X. α-Humulene inhibits hepatocellular carcinoma cell proliferation and induces apoptosis through the inhibition of Akt signaling. Food Chem Toxicol 2019;134:110830. [PMID: 31562948 DOI: 10.1016/j.fct.2019.110830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
556 Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut 2019;68:1287-96. [PMID: 30901310 DOI: 10.1136/gutjnl-2018-317632] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
557 Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40:9-14. [PMID: 26336998 DOI: 10.1016/j.clinre.2015.07.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
558 Tran QH, Nguyen VG, Tran CM, Nguyen MN. Down-regulation of solute carrier family 10 member 1 is associated with early recurrence and poorer prognosis of hepatocellular carcinoma. Heliyon 2021;7:e06463. [PMID: 33763615 DOI: 10.1016/j.heliyon.2021.e06463] [Reference Citation Analysis]
559 Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 2016; 22(41): 9069-9095 [PMID: 27895396 DOI: 10.3748/wjg.v22.i41.9069] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 79] [Article Influence: 13.0] [Reference Citation Analysis]
560 Niu Y, Chen L, Wu M, Huang W, Wu X, Huang D, Xie Y, Shi G. Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma. Virus Res. 2021;293:198264. [PMID: 33359549 DOI: 10.1016/j.virusres.2020.198264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
561 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]